{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:07:41Z","timestamp":1794506861536,"version":"4.9.1"},"reference-count":369,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr Metab (Lond)"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy remains a foundation of cancer care but is limited by multidrug resistance, systemic toxicities, and suboptimal selectivity, prompting interest in adjunctive strategies that improve efficacy and tolerability without adding significant burden to patients or healthcare systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims\/Objectives<\/jats:title>\n                    <jats:p>This review highlights evidence on natural bioactive compounds, including polyphenols, alkaloids, terpenoids, and fungal metabolites, as adjuvants to standard chemotherapeutics, with objectives to: first, delineate mechanisms by which these agents enhance cytotoxic efficacy and overcome resistance; second, summarize preclinical and clinical combination data; and third, evaluate their potential to mitigate chemotherapy-induced organ toxicities through pathway modulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Natural bioactives modulate key oncogenic and stress-response pathways, such as NF-\u03baB, PI3K\/AKT\/mTOR, and NRF2\/HO-1, thereby sensitizing tumors to chemotherapy, attenuating pro-survival signaling, and enhancing apoptosis while reducing inflammatory and oxidative injury in normal tissues. Exemplary combinations, including curcumin with 5\u2011fluorouracil and resveratrol with cisplatin, have demonstrated improved antitumor activity and reduced toxicity in preclinical models, with early clinical observations supporting feasibility and safety in selected settings. Additionally, several compounds exhibit organ-protective effects against cardiotoxicity, nephrotoxicity, neurotoxicity, and gastrointestinal injury induced by chemotherapy, suggesting dual benefits on efficacy and tolerability profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Integrating natural bioactives with conventional chemotherapy represents a promising strategy to enhance therapeutic index by concurrently amplifying antitumor mechanisms and mitigating dose\u2011limiting toxicities, though broader clinical validation and standardized quality controls are needed for routine adoption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12986-026-01094-4","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:54:56Z","timestamp":1771660496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Natural bioactive molecules and chemotherapeutics synergism for enhanced cancer therapy"],"prefix":"10.1186","volume":"23","author":[{"given":"Mehrdad","family":"Hashemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Heshmatzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazaleh","family":"Shahsavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Tavakolpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Komeilie Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardis","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naghmeh","family":"Beikzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Mashhadikhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevda","family":"Nasirzade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Vasheghani Farahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Zali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Taheriazam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Maghrebi-Ghojogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Alimohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payman","family":"Rahimzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiavash","family":"Hushmandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maliheh","family":"Entezari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"issue":"3","key":"1094_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1094_CR2","doi-asserted-by":"publisher","unstructured":"Anand U et al. Corrigendum to \u2018Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics\u2019 [Genes & Diseases 10 (2023) 1367\u20131401]. Genes Dis. 2024;11(4):101211.https:\/\/doi.org\/10.1016\/j.gendis.2024.101211","DOI":"10.1016\/j.gendis.2024.101211"},{"issue":"5","key":"1094_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"issue":"1","key":"1094_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27\u201347. https:\/\/doi.org\/10.1016\/j.cmet.2015.12.006.","journal-title":"Cell Metab"},{"issue":"6","key":"1094_CR5","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/ijc.28261","volume":"134","author":"F Li","year":"2014","unstructured":"Li F, Zhao C, Wang L. Molecular-targeted agents combination therapy for cancer: developments and potentials. Int J Cancer. 2014;134(6):1257\u201369.","journal-title":"Int J Cancer"},{"key":"1094_CR6","doi-asserted-by":"publisher","unstructured":"Buhrmann C, et al. Resveratrol chemosensitizes TNF-\u03b2-Induced survival of 5-FU-Treated colorectal cancer cells. Nutrients. 2018;10(7). https:\/\/doi.org\/10.3390\/nu10070888.","DOI":"10.3390\/nu10070888"},{"key":"1094_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12885-015-1291-0","volume":"15","author":"M Shakibaei","year":"2015","unstructured":"Shakibaei M, et al. Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. BMC Cancer. 2015;15:250. https:\/\/doi.org\/10.1186\/s12885-015-1291-0.","journal-title":"BMC Cancer"},{"issue":"4","key":"1094_CR8","doi-asserted-by":"publisher","first-page":"e0125402","DOI":"10.1371\/journal.pone.0125402","volume":"10","author":"X Wang","year":"2015","unstructured":"Wang X, et al. EGCG enhances cisplatin sensitivity by regulating expression of the copper and cisplatin influx transporter CTR1 in ovary cancer. PLoS ONE. 2015;10(4):e0125402. https:\/\/doi.org\/10.1371\/journal.pone.0125402.","journal-title":"PLoS ONE"},{"issue":"17","key":"1094_CR9","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.2174\/138161209788453167","volume":"15","author":"A Keibel","year":"2009","unstructured":"Keibel A, Singh V, Sharma MC. Inflammation, microenvironment, and the immune system in cancer progression. Curr Pharm Design. 2009;15(17):1949\u201355.","journal-title":"Curr Pharm Design"},{"issue":"4","key":"1094_CR10","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/mco2.104","volume":"2","author":"T Zhang","year":"2021","unstructured":"Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-\u03baB signaling in inflammation and cancer. MedComm (2020). 2021;2(4):618\u201353. https:\/\/doi.org\/10.1002\/mco2.104.","journal-title":"MedComm (2020)"},{"issue":"2","key":"1094_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.20517\/cdr.2019.10","volume":"2","author":"X Wang","year":"2019","unstructured":"Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141\u201360. https:\/\/doi.org\/10.20517\/cdr.2019.10.","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"1094_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00253-012-4128-7","volume":"95","author":"S Chandra","year":"2012","unstructured":"Chandra S. Endophytic fungi: novel sources of anticancer lead molecules. Appl Microbiol Biotechnol. 2012;95(1):47\u201359. https:\/\/doi.org\/10.1007\/s00253-012-4128-7.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"21","key":"1094_CR13","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1016\/j.bmc.2005.05.066","volume":"13","author":"V Srivastava","year":"2005","unstructured":"Srivastava V, Negi AS, Kumar JK, Gupta MM, Khanuja SP. Plant-based anticancer molecules: a chemical and biological profile of some important leads. Bioorg Med Chem. 2005;13(21):5892\u2013908. https:\/\/doi.org\/10.1016\/j.bmc.2005.05.066.","journal-title":"Bioorg Med Chem"},{"key":"1094_CR14","doi-asserted-by":"crossref","unstructured":"Newman DJ, Cragg GM. The discovery of anticancer drugs from natural sources. Natural Products: Drug Discovery and Therapeutic Medicine: Springer; 2005. pp. 129\u2009\u2013\u200968.","DOI":"10.1007\/978-1-59259-976-9_7"},{"key":"1094_CR15","doi-asserted-by":"crossref","unstructured":"Pengelly A. The constituents of medicinal plants: an introduction to the chemistry and therapeutics of herbal medicine. Routledge; 2020.","DOI":"10.4324\/9781003117964"},{"issue":"23","key":"1094_CR16","doi-asserted-by":"publisher","first-page":"8367","DOI":"10.3390\/molecules27238367","volume":"27","author":"A Naeem","year":"2022","unstructured":"Naeem A, et al. Natural products as anticancer agents: current status and future perspectives. Molecules. 2022;27(23):8367.","journal-title":"Molecules"},{"key":"1094_CR17","doi-asserted-by":"publisher","unstructured":"Asma ST, et al. Natural Products\/Bioactive compounds as a source of anticancer drugs. Cancers (Basel). 2022;14(24). https:\/\/doi.org\/10.3390\/cancers14246203.","DOI":"10.3390\/cancers14246203"},{"issue":"5","key":"1094_CR18","first-page":"427","volume":"8","author":"H-Y Sohn","year":"1998","unstructured":"Sohn H-Y, Okos M-R. Paclitaxel (taxol): from nutt to drug. J Microbiol Biotechnol. 1998;8(5):427\u201340.","journal-title":"J Microbiol Biotechnol"},{"issue":"3","key":"1094_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/s0378-8741(00)00341-x","volume":"73","author":"JG Graham","year":"2000","unstructured":"Graham JG, Quinn ML, Fabricant DS, Farnsworth NR. Plants used against cancer - an extension of the work of Jonathan Hartwell. J Ethnopharmacol. 2000;73(3):347\u201377. https:\/\/doi.org\/10.1016\/s0378-8741(00)00341-x.","journal-title":"J Ethnopharmacol"},{"issue":"1\u20132","key":"1094_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jep.2005.05.011","volume":"100","author":"GM Cragg","year":"2005","unstructured":"Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol. 2005;100(1\u20132):72\u20139. https:\/\/doi.org\/10.1016\/j.jep.2005.05.011.","journal-title":"J Ethnopharmacol"},{"issue":"sup1","key":"1094_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3109\/13880209509067087","volume":"33","author":"A Kinghorn","year":"1995","unstructured":"Kinghorn A, et al. Novel strategies for plant-derived anticancer agents. Int J Pharmacognosy. 1995;33(sup1):48\u201358.","journal-title":"Int J Pharmacognosy"},{"issue":"8","key":"1094_CR22","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1055\/s-2004-827198","volume":"70","author":"AD Kinghorn","year":"2004","unstructured":"Kinghorn AD, et al. Natural inhibitors of carcinogenesis. Planta Med. 2004;70(8):691\u2013705. https:\/\/doi.org\/10.1055\/s-2004-827198.","journal-title":"Planta Med"},{"key":"1094_CR23","unstructured":"Powis G. Anticancer drugs: antimetabolite metabolism and natural anticancer agents. (No Title). 1994."},{"issue":"5","key":"1094_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4103\/0250-474x.78541","volume":"72","author":"AK Verma","year":"2010","unstructured":"Verma AK, Singh RR. Induced Dwarf mutant in catharanthus roseus with enhanced antibacterial activity. Indian J Pharm Sci. 2010;72(5):655\u20137. https:\/\/doi.org\/10.4103\/0250-474x.78541.","journal-title":"Indian J Pharm Sci"},{"issue":"8","key":"1094_CR25","first-page":"2212","volume":"51","author":"MA Jordan","year":"1991","unstructured":"Jordan MA, Thrower D, Wilson L. Mechanism of Inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 1991;51(8):2212\u201322.","journal-title":"Cancer Res"},{"issue":"6","key":"1094_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s13205-023-03636-6","volume":"13","author":"A Banyal","year":"2023","unstructured":"Banyal A, et al. Vinca alkaloids as a potential cancer therapeutics: recent update and future challenges. 3 Biotech. 2023;13(6):211. https:\/\/doi.org\/10.1007\/s13205-023-03636-6.","journal-title":"3 Biotech"},{"issue":"6","key":"1094_CR27","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/1078-0432.Ccr-07-2219","volume":"14","author":"J Bennouna","year":"2008","unstructured":"Bennouna J, Delord JP, Campone M, Nguyen L. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res. 2008;14(6):1625\u201332. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-2219.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1094_CR28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/s0006-2952(97)00505-4","volume":"55","author":"A Kruczynski","year":"1998","unstructured":"Kruczynski A, et al. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol. 1998;55(5):635\u201348. https:\/\/doi.org\/10.1016\/s0006-2952(97)00505-4.","journal-title":"Biochem Pharmacol"},{"key":"1094_CR29","doi-asserted-by":"publisher","first-page":"113321DOI","DOI":"10.1016\/j.phytochem.2022.113321","volume":"202","author":"Z Cao","year":"2022","unstructured":"Cao Z, et al. Isoquinoline alkaloids from hylomecon Japonica and their potential anti-breast cancer activities. Phytochemistry. 2022;202:113321DOI. https:\/\/doi.org\/10.1016\/j.phytochem.2022.113321.","journal-title":"Phytochemistry"},{"issue":"1","key":"1094_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41420-022-00936-3","volume":"8","author":"JL Freeling","year":"2022","unstructured":"Freeling JL, et al. Pre-clinical safety and therapeutic efficacy of a plant-based alkaloid in a human colon cancer xenograft model. Cell Death Discov. 2022;8(1):135. https:\/\/doi.org\/10.1038\/s41420-022-00936-3.","journal-title":"Cell Death Discov"},{"issue":"1","key":"1094_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3892\/ol.2020.12331","volume":"21","author":"L Liu","year":"2021","unstructured":"Liu L, et al. Proliferation, migration and invasion of triple negative breast cancer cells are suppressed by berbamine via the PI3K\/Akt\/MDM2\/p53 and PI3K\/Akt\/mTOR signaling pathways. Oncol Lett. 2021;21(1):70. https:\/\/doi.org\/10.3892\/ol.2020.12331.","journal-title":"Oncol Lett"},{"issue":"5","key":"1094_CR32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1208\/s12249-020-01710-3","volume":"21","author":"SS Esnaashari","year":"2020","unstructured":"Esnaashari SS, Muhammadnejad S, Amanpour S, Amani A. A combinational approach towards treatment of breast cancer: an analysis of Noscapine-Loaded polymeric nanoparticles and doxorubicin. AAPS PharmSciTech. 2020;21(5):166. https:\/\/doi.org\/10.1208\/s12249-020-01710-3.","journal-title":"AAPS PharmSciTech"},{"issue":"27","key":"1094_CR33","doi-asserted-by":"publisher","first-page":"14873","DOI":"10.1016\/S0021-9258(17)38654-4","volume":"260","author":"YH Hsiang","year":"1985","unstructured":"Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985;260(27):14873\u20138.","journal-title":"J Biol Chem"},{"issue":"4","key":"1094_CR34","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1200\/jco.1996.14.4.1236","volume":"14","author":"W Dahut","year":"1996","unstructured":"Dahut W, et al. Phase I and Pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol. 1996;14(4):1236\u201344. https:\/\/doi.org\/10.1200\/jco.1996.14.4.1236.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1094_CR35","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1200\/jco.1997.15.8.2905","volume":"15","author":"R Pazdur","year":"1997","unstructured":"Pazdur R, et al. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. J Clin Oncol. 1997;15(8):2905\u20139. https:\/\/doi.org\/10.1200\/jco.1997.15.8.2905.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1094_CR36","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/annonc\/mdl439","volume":"18","author":"L Scott","year":"2007","unstructured":"Scott L, et al. A multicentre phase I and Pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. Ann Oncol. 2007;18(3):569\u201375. https:\/\/doi.org\/10.1093\/annonc\/mdl439.","journal-title":"Ann Oncol"},{"issue":"1","key":"1094_CR37","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1158\/1078-0432.Ccr-08-1024","volume":"15","author":"AX Zhu","year":"2009","unstructured":"Zhu AX, et al. Phase I and Pharmacokinetic study of Gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15(1):374\u201381. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-1024.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1094_CR38","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/annonc\/mdp514","volume":"21","author":"S Pecorelli","year":"2010","unstructured":"Pecorelli S, et al. Phase II of oral Gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Ann Oncol. 2010;21(4):759\u201365. https:\/\/doi.org\/10.1093\/annonc\/mdp514.","journal-title":"Ann Oncol"},{"issue":"2","key":"1094_CR39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00280-012-1906-y","volume":"70","author":"IF Troc\u00f3niz","year":"2012","unstructured":"Troc\u00f3niz IF, et al. Population pharmacokinetic\/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, Elomotecan (BN80927), in a phase I dose finding study in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012;70(2):239\u201350. https:\/\/doi.org\/10.1007\/s00280-012-1906-y.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"24","key":"1094_CR40","doi-asserted-by":"publisher","first-page":"6144","DOI":"10.1002\/cncr.27647","volume":"118","author":"R Kurzrock","year":"2012","unstructured":"Kurzrock R, et al. Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer. 2012;118(24):6144\u201351. https:\/\/doi.org\/10.1002\/cncr.27647.","journal-title":"Cancer"},{"issue":"3","key":"1094_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s0300-9084(98)80004-7","volume":"80","author":"TF Imbert","year":"1998","unstructured":"Imbert TF. Discovery of Podophyllotoxins. Biochimie. 1998;80(3):207\u201322. https:\/\/doi.org\/10.1016\/s0300-9084(98)80004-7.","journal-title":"Biochimie"},{"issue":"4","key":"1094_CR42","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3390\/biom11040603","volume":"11","author":"Z Shah","year":"2021","unstructured":"Shah Z, et al. Podophyllotoxin: history, recent advances and future prospects. Biomolecules. 2021;11(4):603.","journal-title":"Biomolecules"},{"issue":"10","key":"1094_CR43","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/biot.200790106","volume":"2","author":"R Renneberg","year":"2007","unstructured":"Renneberg R, Biotech, History. Yew trees, Paclitaxel synthesis and fungi. Biotechnol J. 2007;2(10):1207\u20139. https:\/\/doi.org\/10.1002\/biot.200790106.","journal-title":"Biotechnol J"},{"issue":"1","key":"1094_CR44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/bf02592403","volume":"24","author":"R Foa","year":"1994","unstructured":"Foa R, Norton L, Seidman AD. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int J Clin Lab Res. 1994;24(1):6\u201314. https:\/\/doi.org\/10.1007\/bf02592403.","journal-title":"Int J Clin Lab Res"},{"issue":"3","key":"1094_CR45","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/00001813-199506000-00001","volume":"6","author":"MC Bissery","year":"1995","unstructured":"Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs. 1995;6(3):339\u201355. https:\/\/doi.org\/10.1097\/00001813-199506000-00001. 63\u2009\u2013\u20098.DOI:.","journal-title":"Anticancer Drugs"},{"issue":"8932","key":"1094_CR46","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/s0140-6736(94)90754-4","volume":"344","author":"K Gelmon","year":"1994","unstructured":"Gelmon K. The taxoids: Paclitaxel and docetaxel. Lancet. 1994;344(8932):1267\u201372. https:\/\/doi.org\/10.1016\/s0140-6736(94)90754-4.","journal-title":"Lancet"},{"issue":"Pt 2","key":"1094_CR47","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1042\/bj3260539","volume":"326","author":"E Beaulieu","year":"1997","unstructured":"Beaulieu E, Demeule M, Ghitescu L, B\u00e9liveau R. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J. 1997;326(Pt 2):539\u201344. https:\/\/doi.org\/10.1042\/bj3260539.","journal-title":"Biochem J"},{"issue":"9","key":"1094_CR48","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1172\/jci15451","volume":"110","author":"S Fellner","year":"2002","unstructured":"Fellner S, et al. Transport of Paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002;110(9):1309\u201318. https:\/\/doi.org\/10.1172\/jci15451.","journal-title":"J Clin Invest"},{"issue":"7","key":"1094_CR49","first-page":"2849","volume":"9","author":"EM Kemper","year":"2003","unstructured":"Kemper EM, et al. Increased penetration of Paclitaxel into the brain by Inhibition of P-Glycoprotein. Clin Cancer Res. 2003;9(7):2849\u201355.","journal-title":"Clin Cancer Res"},{"key":"1094_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/dddt.S13029","volume":"5","author":"CJ Paller","year":"2011","unstructured":"Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2011;5:117\u201324. https:\/\/doi.org\/10.2147\/dddt.S13029.","journal-title":"Drug Des Devel Ther"},{"key":"1094_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/jep.S7804","volume":"3","author":"R Bao","year":"2011","unstructured":"Bao R, Chan P. Novel compounds in the treatment of lung cancer: current and developing therapeutic agents. J Exp Pharmacol. 2011;3:21\u201334. https:\/\/doi.org\/10.2147\/jep.S7804.","journal-title":"J Exp Pharmacol"},{"issue":"1","key":"1094_CR52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/138161211795049778","volume":"17","author":"M Wetzler","year":"2011","unstructured":"Wetzler M, Segal D. Omacetaxine as an anticancer therapeutic: what is old is new again. Curr Pharm Des. 2011;17(1):59\u201364. https:\/\/doi.org\/10.2174\/138161211795049778.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"1094_CR53","first-page":"1","volume":"17","author":"RS Fallen","year":"2012","unstructured":"Fallen RS, Gooderham M. Ingenol mebutate: an introduction. Skin Therapy Lett. 2012;17(2):1\u20133.","journal-title":"Skin Therapy Lett"},{"issue":"10","key":"1094_CR54","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nm1095-1046","volume":"1","author":"E Pisha","year":"1995","unstructured":"Pisha E, et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med. 1995;1(10):1046\u201351. https:\/\/doi.org\/10.1038\/nm1095-1046.","journal-title":"Nat Med"},{"issue":"1\u20132","key":"1094_CR55","first-page":"33","volume":"30","author":"C Onwuchekwa","year":"2015","unstructured":"Onwuchekwa C, Oluwole FS. Anti-Gastric ulcer effect of betulinic acid in male albino rats. Niger J Physiol Sci. 2015;30(1\u20132):33\u20137.","journal-title":"Niger J Physiol Sci"},{"issue":"28","key":"1094_CR56","doi-asserted-by":"publisher","first-page":"6977","DOI":"10.1021\/jf3006728","volume":"60","author":"AG Tzakos","year":"2012","unstructured":"Tzakos AG, et al. Exploration of the antiplatelet activity profile of betulinic acid on human platelets. J Agric Food Chem. 2012;60(28):6977\u201383. https:\/\/doi.org\/10.1021\/jf3006728.","journal-title":"J Agric Food Chem"},{"key":"1094_CR57","doi-asserted-by":"publisher","first-page":"113628DOI","DOI":"10.1016\/j.biopha.2022.113628","volume":"154","author":"S Dai","year":"2022","unstructured":"Dai S, et al. Aqueous extract of taxus chinensis var. Mairei targeting CD47 enhanced antitumor effects in non-small cell lung cancer. Biomed Pharmacother. 2022;154:113628DOI. https:\/\/doi.org\/10.1016\/j.biopha.2022.113628.","journal-title":"Biomed Pharmacother"},{"key":"1094_CR58","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.carbpol.2015.06.107","volume":"133","author":"M Wu","year":"2015","unstructured":"Wu M, Zhang F, Yu Z, Lin J, Yang L. Chemical characterization and in vitro antitumor activity of a single-component polysaccharide from taxus chinensis var. Mairei. Carbohydr Polym. 2015;133:294\u2013301. https:\/\/doi.org\/10.1016\/j.carbpol.2015.06.107.","journal-title":"Carbohydr Polym"},{"issue":"7","key":"1094_CR59","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/S0040-4020(01)90352-7","volume":"44","author":"RG Naik","year":"1988","unstructured":"Naik RG, et al. An antiinflammatory cum Immunomodulatory Piperidinylbenzopyranone from dysoxylum binectariferum: isolation, structure and total synthesis. Tetrahedron. 1988;44(7):2081\u20136.","journal-title":"Tetrahedron"},{"issue":"34","key":"1094_CR60","doi-asserted-by":"publisher","first-page":"31793","DOI":"10.1074\/jbc.M102306200","volume":"276","author":"SH Chao","year":"2001","unstructured":"Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem. 2001;276(34):31793\u20139. https:\/\/doi.org\/10.1074\/jbc.M102306200.","journal-title":"J Biol Chem"},{"issue":"1","key":"1094_CR61","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/s0006-291x(02)00266-8","volume":"293","author":"WF de Azevedo Jr","year":"2002","unstructured":"de Azevedo WF Jr., Canduri F, da Silveira NJ. Structural basis for Inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun. 2002;293(1):566\u201371. https:\/\/doi.org\/10.1016\/s0006-291x(02)00266-8.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"1094_CR62","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1182\/blood-2007-10-115733","volume":"111","author":"SR Hussain","year":"2008","unstructured":"Hussain SR, et al. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood. 2008;111(6):3190\u20139. https:\/\/doi.org\/10.1182\/blood-2007-10-115733.","journal-title":"Blood"},{"issue":"12 Pt 2","key":"1094_CR63","doi-asserted-by":"publisher","first-page":"s4270","DOI":"10.1158\/1078-0432.Ccr-040020","volume":"10","author":"GI Shapiro","year":"2004","unstructured":"Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res. 2004;10(12 Pt 2):s4270\u20135. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-040020.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1094_CR64","first-page":"65","volume":"55","author":"M Akram","year":"2010","unstructured":"Akram M, et al. Curcuma longa and curcumin: a review Article. Rom J Biol Plant Biol. 2010;55(2):65\u201370.","journal-title":"Rom J Biol Plant Biol"},{"key":"1094_CR65","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1476-4598-10-12","volume":"10","author":"R Wilken","year":"2011","unstructured":"Wilken R, Veena MS, Wang MB, Srivatsan ES, Curcumin. A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer. 2011;10:12. https:\/\/doi.org\/10.1186\/1476-4598-10-12.","journal-title":"Mol Cancer"},{"issue":"4","key":"1094_CR66","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00253-004-1787-z","volume":"67","author":"BZ Zaidman","year":"2005","unstructured":"Zaidman BZ, Yassin M, Mahajna J, Wasser SP. Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol. 2005;67(4):453\u201368. https:\/\/doi.org\/10.1007\/s00253-004-1787-z.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"3","key":"1094_CR67","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s00253-002-1076-7","volume":"60","author":"SP Wasser","year":"2002","unstructured":"Wasser SP. Medicinal mushrooms as a source of antitumor and Immunomodulating polysaccharides. Appl Microbiol Biotechnol. 2002;60(3):258\u201374. https:\/\/doi.org\/10.1007\/s00253-002-1076-7.","journal-title":"Appl Microbiol Biotechnol"},{"key":"1094_CR68","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/s0065-2164(08)70253-3","volume":"37","author":"SC Jong","year":"1992","unstructured":"Jong SC, Birmingham JM. Medicinal benefits of the mushroom ganoderma. Adv Appl Microbiol. 1992;37:101\u201334. https:\/\/doi.org\/10.1016\/s0065-2164(08)70253-3.","journal-title":"Adv Appl Microbiol"},{"key":"1094_CR69","doi-asserted-by":"publisher","first-page":"118917DOI","DOI":"10.1016\/j.carbpol.2021.118917","volume":"278","author":"R Rutckeviski","year":"2022","unstructured":"Rutckeviski R, et al. Agaricus bisporus \u03b2-(1 \u2192 6)-d-glucan induces M1 phenotype on macrophages and increases sensitivity to doxorubicin of triple negative breast cancer cells. Carbohydr Polym. 2022;278:118917DOI. https:\/\/doi.org\/10.1016\/j.carbpol.2021.118917.","journal-title":"Carbohydr Polym"},{"key":"1094_CR70","doi-asserted-by":"publisher","first-page":"113491DOI","DOI":"10.1016\/j.biopha.2022.113491","volume":"153","author":"SY Yoon","year":"2022","unstructured":"Yoon SY, Lindroth AM, Kwon S, Park SJ, Park YJ. Adenosine derivatives from cordyceps exert antitumor effects against ovarian cancer cells through ENT1-mediated transport, induction of AMPK signaling, and consequent autophagic cell death. Biomed Pharmacother. 2022;153:113491DOI. https:\/\/doi.org\/10.1016\/j.biopha.2022.113491.","journal-title":"Biomed Pharmacother"},{"key":"1094_CR71","doi-asserted-by":"publisher","first-page":"826716","DOI":"10.3389\/fphar.2022.826716","volume":"13","author":"K Cen","year":"2022","unstructured":"Cen K, et al. Sporoderm-Broken spores of ganoderma lucidum sensitizes ovarian cancer to cisplatin by ROS\/ERK signaling and attenuates Chemotherapy-Related toxicity. Front Pharmacol. 2022;13:826716. https:\/\/doi.org\/10.3389\/fphar.2022.826716.","journal-title":"Front Pharmacol"},{"key":"1094_CR72","doi-asserted-by":"publisher","first-page":"100308","DOI":"10.1016\/j.bcdf.2022.100308","volume":"27","author":"A Thimmaraju","year":"2022","unstructured":"Thimmaraju A, Govindan S. Novel studies of characterization, antioxidant, anticoagulant and anticancer activity of purified polysaccharide from hypsizygus Ulmarius mushroom. Bioactive Carbohydr Diet Fibre. 2022;27:100308.","journal-title":"Bioactive Carbohydr Diet Fibre"},{"issue":"11","key":"1094_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/IntJMedMushrooms.2022045181","volume":"24","author":"T Fekry","year":"2022","unstructured":"Fekry T, et al. Anticancer properties of Selenium-Enriched oyster Culinary-Medicinal Mushroom, pleurotus ostreatus (Agaricomycetes), in colon cancer in vitro. Int J Med Mushrooms. 2022;24(11):1\u201320. https:\/\/doi.org\/10.1615\/IntJMedMushrooms.2022045181.","journal-title":"Int J Med Mushrooms"},{"issue":"1","key":"1094_CR74","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10719-021-09972-0","volume":"38","author":"T Meng","year":"2021","unstructured":"Meng T, Yu SS, Ji HY, Xu XM, Liu AJ. A novel acid polysaccharide from boletus edulis: extraction, characteristics and antitumor activities in vitro. Glycoconj J. 2021;38(1):13\u201324. https:\/\/doi.org\/10.1007\/s10719-021-09972-0.","journal-title":"Glycoconj J"},{"key":"1094_CR75","doi-asserted-by":"publisher","first-page":"102641","DOI":"10.1016\/j.jddst.2021.102641","volume":"64","author":"\u00d6 Kaplan","year":"2021","unstructured":"Kaplan \u00d6, et al. Microwave-assisted green synthesis of silver nanoparticles using crude extracts of boletus Edulis and coriolus versicolor: Characterization, anticancer, antimicrobial and wound healing activities. J Drug Deliv Sci Technol. 2021;64:102641.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1094_CR76","doi-asserted-by":"publisher","unstructured":"Hetland G, et al. Antitumor, Anti-Inflammatory and antiallergic effects of agaricus Blazei mushroom extract and the related medicinal basidiomycetes mushrooms, hericium Erinaceus and Grifola frondosa: A review of preclinical and clinical studies. Nutrients. 2020;12(5). https:\/\/doi.org\/10.3390\/nu12051339.","DOI":"10.3390\/nu12051339"},{"key":"1094_CR77","doi-asserted-by":"publisher","unstructured":"Misgiati M, Widyawaruyanti A, Joko Raharjo S, Sukardiman S. Ergosterol isolated from agaricus Blazei murill n-hexane extracts as potential anticancer MCF-7 activity.Pharmacognosy J. 2021;13(2):418-26. https:\/\/doi.org\/10.5530\/pj.2021.13.53","DOI":"10.5530\/pj.2021.13.53"},{"issue":"5","key":"1094_CR78","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3892\/ol.2020.12133","volume":"20","author":"Y Sun","year":"2020","unstructured":"Sun Y, et al. Agaricus Blazei extract (FA-2-b-\u03b2) induces apoptosis in chronic myeloid leukemia cells. Oncol Lett. 2020;20(5):270. https:\/\/doi.org\/10.3892\/ol.2020.12133.","journal-title":"Oncol Lett"},{"key":"1094_CR79","doi-asserted-by":"publisher","first-page":"580656DOI","DOI":"10.3389\/fphar.2020.580656","volume":"11","author":"M Jeitler","year":"2020","unstructured":"Jeitler M, et al. Significance of medicinal mushrooms in integrative oncology: A narrative review. Front Pharmacol. 2020;11:580656DOI. https:\/\/doi.org\/10.3389\/fphar.2020.580656.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1094_CR80","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1089\/acm.2016.0136","volume":"23","author":"WY Chay","year":"2017","unstructured":"Chay WY, et al. Coriolus versicolor (Yunzhi) use as therapy in advanced hepatocellular carcinoma patients with poor liver function or who are unfit for standard therapy. J Altern Complement Med. 2017;23(8):648\u201352. https:\/\/doi.org\/10.1089\/acm.2016.0136.","journal-title":"J Altern Complement Med"},{"issue":"17","key":"1094_CR81","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1002\/cncr.29421","volume":"121","author":"P Twardowski","year":"2015","unstructured":"Twardowski P, et al. A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: roles of cytokines and myeloid-derived suppressor cells for agaricus bisporus-induced prostate-specific antigen responses. Cancer. 2015;121(17):2942\u201350. https:\/\/doi.org\/10.1002\/cncr.29421.","journal-title":"Cancer"},{"key":"1094_CR82","doi-asserted-by":"publisher","first-page":"251632","DOI":"10.5402\/2012\/251632","volume":"2012","author":"CJ Torkelson","year":"2012","unstructured":"Torkelson CJ, et al. Phase 1 clinical trial of trametes versicolor in women with breast cancer. ISRN Oncol. 2012;2012:251632. https:\/\/doi.org\/10.5402\/2012\/251632.","journal-title":"ISRN Oncol"},{"issue":"1","key":"1094_CR83","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/era.10.196","volume":"11","author":"R Mamtani","year":"2011","unstructured":"Mamtani R, Vaughn DJ. Vinflunine in the treatment of advanced bladder cancer. Expert Rev Anticancer Ther. 2011;11(1):13\u201320. https:\/\/doi.org\/10.1586\/era.10.196.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9582","key":"1094_CR84","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0140-6736(07)61086-1","volume":"370","author":"M Koopman","year":"2007","unstructured":"Koopman M, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007;370(9582):135\u201342. https:\/\/doi.org\/10.1016\/s0140-6736(07)61086-1.","journal-title":"Lancet"},{"issue":"10","key":"1094_CR85","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.phymed.2016.06.013","volume":"23","author":"S Lin","year":"2016","unstructured":"Lin S, et al. MHP-1 inhibits cancer metastasis and restores Topotecan sensitivity via regulating epithelial-mesenchymal transition and TGF-\u03b2 signaling in human breast cancer cells. Phytomedicine. 2016;23(10):1053\u201363. https:\/\/doi.org\/10.1016\/j.phymed.2016.06.013.","journal-title":"Phytomedicine"},{"key":"1094_CR86","doi-asserted-by":"publisher","unstructured":"Abu Samaan TM, Samec M, Liskova A, Kubatka P, B\u00fcsselberg D. Paclitaxel\u2019s Mechanistic and Clinical Effects on Breast Cancer. Biomolecules. 2019;9(12). https:\/\/doi.org\/10.3390\/biom9120789.","DOI":"10.3390\/biom9120789"},{"issue":"1","key":"1094_CR87","doi-asserted-by":"publisher","first-page":"29","DOI":"10.7150\/jca.10336","volume":"6","author":"A Di Lonardo","year":"2015","unstructured":"Di Lonardo A, Nasi S, Pulciani S. Cancer: we should not forget the past. J Cancer. 2015;6(1):29\u201339. https:\/\/doi.org\/10.7150\/jca.10336.","journal-title":"J Cancer"},{"issue":"6","key":"1094_CR88","first-page":"391","volume":"74","author":"RJ Papac","year":"2001","unstructured":"Papac RJ. Origins of cancer therapy. Yale J Biol Med. 2001;74(6):391\u20138.","journal-title":"Yale J Biol Med"},{"issue":"6","key":"1094_CR89","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/j.1939-1676.2010.0590.x","volume":"24","author":"WB Morrison","year":"2010","unstructured":"Morrison WB. Cancer chemotherapy: an annotated history. J Vet Intern Med. 2010;24(6):1249\u201362. https:\/\/doi.org\/10.1111\/j.1939-1676.2010.0590.x.","journal-title":"J Vet Intern Med"},{"issue":"283","key":"1094_CR90","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1086\/353876","volume":"76","author":"JM Riddle","year":"1985","unstructured":"Riddle JM. Ancient and medieval chemotherapy for cancer. Isis. 1985;76(283):319\u201330. https:\/\/doi.org\/10.1086\/353876.","journal-title":"Isis"},{"issue":"15","key":"1094_CR91","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.2174\/1568026615666150414120547","volume":"15","author":"CT Lee","year":"2015","unstructured":"Lee CT, Huang YW, Yang CH, Huang KS. Drug delivery systems and combination therapy by using Vinca alkaloids. Curr Top Med Chem. 2015;15(15):1491\u2013500. https:\/\/doi.org\/10.2174\/1568026615666150414120547.","journal-title":"Curr Top Med Chem"},{"key":"1094_CR92","unstructured":"DeVita VT, DeVita VT Jr, Lawrence TS, Rosenberg SA. Cancer: principles & practice of oncology: primer of the molecular biology of cancer. Lippincott Williams & Wilkins; 2011."},{"issue":"21","key":"1094_CR93","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.Can-07-6611","volume":"68","author":"VT DeVita Jr","year":"2008","unstructured":"DeVita VT Jr., Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643\u201353. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-6611.","journal-title":"Cancer Res"},{"key":"1094_CR94","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.redox.2017.04.018","volume":"12","author":"B Kalyanaraman","year":"2017","unstructured":"Kalyanaraman B. Teaching the basics of cancer metabolism: developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism. Redox Biol. 2017;12:833\u201342. https:\/\/doi.org\/10.1016\/j.redox.2017.04.018.","journal-title":"Redox Biol"},{"issue":"4","key":"1094_CR95","doi-asserted-by":"publisher","first-page":"e2000048","DOI":"10.1002\/bies.202000048","volume":"42","author":"A Moore","year":"2020","unstructured":"Moore A. Metabolic cycles in cancer cells? BioEssays. 2020;42(4):e2000048. https:\/\/doi.org\/10.1002\/bies.202000048.","journal-title":"BioEssays"},{"issue":"1","key":"1094_CR96","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1750-9378-7-33","volume":"7","author":"K Alibek","year":"2012","unstructured":"Alibek K, Bekmurzayeva A, Mussabekova A, Sultankulov B. Using antimicrobial adjuvant therapy in cancer treatment: a review. Infect Agent Cancer. 2012;7(1):33. https:\/\/doi.org\/10.1186\/1750-9378-7-33.","journal-title":"Infect Agent Cancer"},{"key":"1094_CR97","doi-asserted-by":"publisher","unstructured":"Anand U, Jacobo-Herrera N, Altemimi A, Lakhssassi N. A comprehensive review on medicinal plants as antimicrobial therapeutics: potential avenues of biocompatible drug discovery. Metabolites. 2019;9(11). https:\/\/doi.org\/10.3390\/metabo9110258.","DOI":"10.3390\/metabo9110258"},{"key":"1094_CR98","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fonc.2013.00107","volume":"3","author":"TL Whiteside","year":"2013","unstructured":"Whiteside TL. Immune responses to cancer: are they potential biomarkers of prognosis? Front Oncol. 2013;3:107. https:\/\/doi.org\/10.3389\/fonc.2013.00107.","journal-title":"Front Oncol"},{"key":"1094_CR99","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.molmet.2019.08.021","volume":"33","author":"P Kreuzaler","year":"2020","unstructured":"Kreuzaler P, Panina Y, Segal J, Yuneva M. Adapt and conquer: metabolic flexibility in cancer growth, invasion and evasion. Mol Metab. 2020;33:83\u2013101. https:\/\/doi.org\/10.1016\/j.molmet.2019.08.021.","journal-title":"Mol Metab"},{"key":"1094_CR100","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13046-015-0221-y","volume":"34","author":"GJ Yoshida","year":"2015","unstructured":"Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015;34:111. https:\/\/doi.org\/10.1186\/s13046-015-0221-y.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"1094_CR101","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/cncr.30430","volume":"123","author":"EA Mroz","year":"2017","unstructured":"Mroz EA, Rocco JW. The challenges of tumor genetic diversity. Cancer. 2017;123(6):917\u201327. https:\/\/doi.org\/10.1002\/cncr.30430.","journal-title":"Cancer"},{"issue":"7","key":"1094_CR102","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer AC, Sorger PK. Combination cancer therapy can confer benefit via Patient-to-Patient variability without drug additivity or synergy. Cell. 2017;171(7):1678\u201391. https:\/\/doi.org\/10.1016\/j.cell.2017.11.009.","journal-title":"Cell"},{"key":"1094_CR103","doi-asserted-by":"publisher","first-page":"543531","DOI":"10.4061\/2010\/543531","volume":"2010","author":"N Kondo","year":"2010","unstructured":"Kondo N, Takahashi A, Ono K, Ohnishi T. DNA damage induced by alkylating agents and repair pathways. J Nucleic Acids. 2010;2010:543531. https:\/\/doi.org\/10.4061\/2010\/543531.","journal-title":"J Nucleic Acids"},{"key":"1094_CR104","doi-asserted-by":"publisher","first-page":"8DOI","DOI":"10.1186\/s40170-017-0170-3","volume":"5","author":"M Mehrmohamadi","year":"2017","unstructured":"Mehrmohamadi M, Jeong SH, Locasale JW. Molecular features that predict the response to antimetabolite chemotherapies. Cancer Metab. 2017;5:8DOI. https:\/\/doi.org\/10.1186\/s40170-017-0170-3.","journal-title":"Cancer Metab"},{"issue":"2","key":"1094_CR105","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/00003495-198530020-00003","volume":"30","author":"DG Lambie","year":"1985","unstructured":"Lambie DG, Johnson RH. Drugs and folate metabolism. Drugs. 1985;30(2):145\u201355. https:\/\/doi.org\/10.2165\/00003495-198530020-00003.","journal-title":"Drugs"},{"key":"1094_CR106","doi-asserted-by":"publisher","unstructured":"Raimondi MV, et al. DHFR inhibitors: reading the past for discovering novel anticancer agents. Molecules. 2019;24(6). https:\/\/doi.org\/10.3390\/molecules24061140.","DOI":"10.3390\/molecules24061140"},{"issue":"11","key":"1094_CR107","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","volume":"364","author":"B L\u00f6wenberg","year":"2011","unstructured":"L\u00f6wenberg B, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364(11):1027\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1010222.","journal-title":"N Engl J Med"},{"issue":"1","key":"1094_CR108","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2017017912","volume":"34","author":"S Dyawanapelly","year":"2017","unstructured":"Dyawanapelly S, Kumar A, Chourasia MK. Lessons learned from gemcitabine: impact of therapeutic carrier systems and gemcitabine\u2019s drug conjugates on cancer therapy. Crit Rev Ther Drug Carrier Syst. 2017;34(1):63\u201396. https:\/\/doi.org\/10.1615\/CritRevTherDrugCarrierSyst.2017017912.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"4","key":"1094_CR109","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1023\/a:1006416410198","volume":"18","author":"JL Grem","year":"2000","unstructured":"Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000;18(4):299\u2013313. https:\/\/doi.org\/10.1023\/a:1006416410198.","journal-title":"Invest New Drugs"},{"key":"1094_CR110","doi-asserted-by":"crossref","unstructured":"Hasegawa K, et al. Oral adjuvant chemotherapy using uracil-tegafur (UFT) with leucovorin (LV) after resection of colorectal cancer liver metastases: Long-term survival results of the phase III UFT\/LV study. American Society of Clinical Oncology; 2017.","DOI":"10.1200\/JCO.2017.35.4_suppl.672"},{"issue":"2","key":"1094_CR111","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.clinre.2013.11.006","volume":"38","author":"Y Liu","year":"2014","unstructured":"Liu Y, et al. Raltitrexed-based chemotherapy for advanced colorectal cancer. Clin Res Hepatol Gastroenterol. 2014;38(2):219\u201325. https:\/\/doi.org\/10.1016\/j.clinre.2013.11.006.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1094_CR112","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/cmar.S40600","volume":"6","author":"P Malik","year":"2014","unstructured":"Malik P, Cashen AF. Decitabine in the treatment of acute myeloid leukemia in elderly patients. Cancer Manag Res. 2014;6:53\u201361. https:\/\/doi.org\/10.2147\/cmar.S40600.","journal-title":"Cancer Manag Res"},{"issue":"22","key":"1094_CR113","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1612645.","journal-title":"N Engl J Med"},{"key":"1094_CR114","unstructured":"Nikolic VD, Savic IM, Nikolic LB, Savic IM. Biosynthesis of Paclitaxel and its pharmaceutical application for cancer treatment. Paclitaxel: Biosynthesis, mechanisms of action and clinical uses. Nova Science Publishers New York; 2013. pp. 101\u201322."},{"issue":"10","key":"1094_CR115","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1080\/15384047.2019.1638678","volume":"20","author":"JC Leung","year":"2019","unstructured":"Leung JC, Cassimeris L. Reorganization of paclitaxel-stabilized microtubule arrays at mitotic entry: roles of depolymerizing kinesins and severing proteins. Cancer Biol Ther. 2019;20(10):1337\u201347. https:\/\/doi.org\/10.1080\/15384047.2019.1638678.","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"1094_CR116","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/cad.0000000000000057","volume":"25","author":"CL Schwab","year":"2014","unstructured":"Schwab CL, English DP, Roque DM, Santin AD. Taxanes: their impact on gynecologic malignancy. Anticancer Drugs. 2014;25(5):522\u201335. https:\/\/doi.org\/10.1097\/cad.0000000000000057.","journal-title":"Anticancer Drugs"},{"key":"1094_CR117","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s11658-019-0164-y","volume":"24","author":"L Zhu","year":"2019","unstructured":"Zhu L, Chen L. Progress in research on Paclitaxel and tumor immunotherapy. Cell Mol Biol Lett. 2019;24:40. https:\/\/doi.org\/10.1186\/s11658-019-0164-y.","journal-title":"Cell Mol Biol Lett"},{"issue":"S2","key":"1094_CR118","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1634\/theoncologist.9-suppl_2-24","volume":"9","author":"J Crown","year":"2004","unstructured":"Crown J, O\u2019Leary M, Ooi W-S. Docetaxel and Paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist. 2004;9(S2):24\u201332.","journal-title":"Oncologist"},{"issue":"4","key":"1094_CR119","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.cbpa.2010.06.170","volume":"14","author":"SC Alley","year":"2010","unstructured":"Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14(4):529\u201337. https:\/\/doi.org\/10.1016\/j.cbpa.2010.06.170.","journal-title":"Curr Opin Chem Biol"},{"issue":"9","key":"1094_CR120","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1021\/am406012g","volume":"6","author":"R Vivek","year":"2014","unstructured":"Vivek R, et al. Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy. ACS Appl Mater Interfaces. 2014;6(9):6469\u201380. https:\/\/doi.org\/10.1021\/am406012g.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"1094_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4143\/crt.2009.41.1.1","volume":"41","author":"X Wang","year":"2009","unstructured":"Wang X, Wang Y, Chen ZG, Shin DM. Advances of cancer therapy by nanotechnology. Cancer Res Treat. 2009;41(1):1\u201311. https:\/\/doi.org\/10.4143\/crt.2009.41.1.1.","journal-title":"Cancer Res Treat"},{"key":"1094_CR122","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1756-8722-5-70","volume":"5","author":"MA Firer","year":"2012","unstructured":"Firer MA, Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol. 2012;5:70. https:\/\/doi.org\/10.1186\/1756-8722-5-70.","journal-title":"J Hematol Oncol"},{"key":"1094_CR123","doi-asserted-by":"publisher","unstructured":"Kutova OM, Guryev EL, Sokolova EA, Alzeibak R, Balalaeva IV. Targeted delivery to tumors: multidirectional strategies to improve treatment efficiency. Cancers (Basel). 2019;11(1). https:\/\/doi.org\/10.3390\/cancers11010068.","DOI":"10.3390\/cancers11010068"},{"issue":"5","key":"1094_CR124","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1158\/1078-0432.Ccr-07-1441","volume":"14","author":"K Cho","year":"2008","unstructured":"Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-1441.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1094_CR125","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","volume":"9","author":"D Rosenblum","year":"2018","unstructured":"Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9(1):1410. https:\/\/doi.org\/10.1038\/s41467-018-03705-y.","journal-title":"Nat Commun"},{"issue":"1","key":"1094_CR126","first-page":"939378","volume":"2014","author":"KB Sutradhar","year":"2014","unstructured":"Sutradhar KB, Amin ML. Nanotechnology in cancer drug delivery and selective targeting. Int Sch Res Notices. 2014;2014(1):939378.","journal-title":"Int Sch Res Notices"},{"issue":"1","key":"1094_CR127","first-page":"4927312","volume":"2019","author":"MZ El-Readi","year":"2019","unstructured":"El-Readi MZ, Althubiti MA. Cancer nanomedicine: a new era of successful targeted therapy. J Nanomaterials. 2019;2019(1):4927312.","journal-title":"J Nanomaterials"},{"key":"1094_CR128","doi-asserted-by":"publisher","unstructured":"Lammers T, et al. Cancer nanomedicine: is targeting our target? Nat Rev Mater. 2016;1(9). https:\/\/doi.org\/10.1038\/natrevmats.2016.69.","DOI":"10.1038\/natrevmats.2016.69"},{"issue":"5","key":"1094_CR129","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/emmm.201000070","volume":"2","author":"D Dias-Santagata","year":"2010","unstructured":"Dias-Santagata D, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2(5):146\u201358. https:\/\/doi.org\/10.1002\/emmm.201000070.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"1094_CR130","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/bjc.2014.476","volume":"112","author":"IV Fedorenko","year":"2015","unstructured":"Fedorenko IV, Gibney GT, Sondak VK, Smalley KS. Beyond BRAF: where next for melanoma therapy? Br J Cancer. 2015;112(2):217\u201326. https:\/\/doi.org\/10.1038\/bjc.2014.476.","journal-title":"Br J Cancer"},{"issue":"7","key":"1094_CR131","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrc3760","volume":"14","author":"M Holderfield","year":"2014","unstructured":"Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14(7):455\u201367. https:\/\/doi.org\/10.1038\/nrc3760.","journal-title":"Nat Rev Cancer"},{"key":"1094_CR132","doi-asserted-by":"publisher","unstructured":"Zaman A, Wu W, Bivona TG, Targeting Oncogenic BRAF. Past, Present, and future. Cancers (Basel). 2019;11(8). https:\/\/doi.org\/10.3390\/cancers11081197.","DOI":"10.3390\/cancers11081197"},{"issue":"7153","key":"1094_CR133","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561\u20136. https:\/\/doi.org\/10.1038\/nature05945.","journal-title":"Nature"},{"issue":"8","key":"1094_CR134","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1502309.","journal-title":"N Engl J Med"},{"issue":"20","key":"1094_CR135","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, et al. Alpelisib for PIK3CA-Mutated, hormone Receptor-Positive advanced breast cancer. N Engl J Med. 2019;380(20):1929\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1813904.","journal-title":"N Engl J Med"},{"issue":"5","key":"1094_CR136","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17(5):318\u201332. https:\/\/doi.org\/10.1038\/nrc.2017.8.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1094_CR137","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.Cd-12-0362","volume":"3","author":"MV Dieci","year":"2013","unstructured":"Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013;3(3):264\u201379. https:\/\/doi.org\/10.1158\/2159-8290.Cd-12-0362.","journal-title":"Cancer Discov"},{"issue":"2","key":"1094_CR138","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123\u201334. https:\/\/doi.org\/10.1056\/NEJMoa0900212.","journal-title":"N Engl J Med"},{"issue":"9737","key":"1094_CR139","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/s0140-6736(10)60892-6","volume":"376","author":"A Tutt","year":"2010","unstructured":"Tutt A, et al. Oral poly(ADP-ribose) polymerase inhibitor Olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235\u201344. https:\/\/doi.org\/10.1016\/s0140-6736(10)60892-6.","journal-title":"Lancet"},{"issue":"10","key":"1094_CR140","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1021\/acs.jnatprod.7b00573","volume":"80","author":"A Chaudhary","year":"2017","unstructured":"Chaudhary A, et al. 2,3-Dihydro-3\u03b2-methoxy Withaferin-A protects normal cells against stress: molecular evidence of its potent cytoprotective activity. J Nat Prod. 2017;80(10):2756\u201360. https:\/\/doi.org\/10.1021\/acs.jnatprod.7b00573.","journal-title":"J Nat Prod"},{"issue":"12","key":"1094_CR141","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nrc4015","volume":"15","author":"AA Friedman","year":"2015","unstructured":"Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015;15(12):747\u201356. https:\/\/doi.org\/10.1038\/nrc4015.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1094_CR142","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3892\/ijo.2018.4661","volume":"54","author":"V Schirrmacher","year":"2019","unstructured":"Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int J Oncol. 2019;54(2):407\u201319. https:\/\/doi.org\/10.3892\/ijo.2018.4661.","journal-title":"Int J Oncol"},{"issue":"4","key":"1094_CR143","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237\u201351. https:\/\/doi.org\/10.1038\/nrc3237.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1094_CR144","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint Blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471\u201382. https:\/\/doi.org\/10.1016\/j.ccell.2019.09.006.","journal-title":"Cancer Cell"},{"issue":"7","key":"1094_CR145","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.it.2016.04.010","volume":"37","author":"PE Hughes","year":"2016","unstructured":"Hughes PE, Caenepeel S, Wu LC. Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer. Trends Immunol. 2016;37(7):462\u201376. https:\/\/doi.org\/10.1016\/j.it.2016.04.010.","journal-title":"Trends Immunol"},{"issue":"11","key":"1094_CR146","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41577-018-0061-z","volume":"18","author":"L Chiossone","year":"2018","unstructured":"Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18(11):671\u201388. https:\/\/doi.org\/10.1038\/s41577-018-0061-z.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"1094_CR147","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/s1470-2045(20)30180-7","volume":"21","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos PA, et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(7):957\u201368. https:\/\/doi.org\/10.1016\/s1470-2045(20)30180-7.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1094_CR148","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2217\/imt-2017-0121","volume":"10","author":"M Reck","year":"2018","unstructured":"Reck M. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer. Immunotherapy. 2018;10(2):93\u2013105. https:\/\/doi.org\/10.2217\/imt-2017-0121.","journal-title":"Immunotherapy"},{"issue":"6","key":"1094_CR149","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-020-01295-y","volume":"80","author":"C Kang","year":"2020","unstructured":"Kang C, Syed YY. Atezolizumab (in combination with Nab-Paclitaxel): A review in advanced Triple-Negative breast cancer. Drugs. 2020;80(6):601\u20137. https:\/\/doi.org\/10.1007\/s40265-020-01295-y.","journal-title":"Drugs"},{"issue":"10","key":"1094_CR150","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","volume":"17","author":"B Allard","year":"2020","unstructured":"Allard B, Allard D, Buisseret L, Stagg J. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020;17(10):611\u201329. https:\/\/doi.org\/10.1038\/s41571-020-0382-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"1094_CR151","doi-asserted-by":"publisher","unstructured":"Pasquini S, Contri C, Borea PA, Vincenzi F, Varani K. Adenosine and inflammation: Here, there and everywhere. Int J Mol Sci. 2021;22(14). https:\/\/doi.org\/10.3390\/ijms22147685.","DOI":"10.3390\/ijms22147685"},{"key":"1094_CR152","doi-asserted-by":"publisher","unstructured":"Franco R, Rivas-Santisteban R, Navarro G, Reyes-Resina I. Adenosine receptor antagonists to combat cancer and to boost Anti-Cancer chemotherapy and immunotherapy. Cells. 2021;10(11). https:\/\/doi.org\/10.3390\/cells10112831.","DOI":"10.3390\/cells10112831"},{"key":"1094_CR153","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.coph.2020.07.003","volume":"53","author":"RS Helms","year":"2020","unstructured":"Helms RS, Powell JD. Rethinking the adenosine-A(2A)R checkpoint: implications for enhancing anti-tumor immunotherapy. Curr Opin Pharmacol. 2020;53:77\u201383. https:\/\/doi.org\/10.1016\/j.coph.2020.07.003.","journal-title":"Curr Opin Pharmacol"},{"issue":"21","key":"1094_CR154","doi-asserted-by":"publisher","first-page":"12196","DOI":"10.1021\/acs.jmedchem.0c00237","volume":"63","author":"F Yu","year":"2020","unstructured":"Yu F, Zhu C, Xie Q, Wang Y, Adenosine. A(2A) receptor antagonists for cancer immunotherapy. J Med Chem. 2020;63(21):12196\u2013212. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00237.","journal-title":"J Med Chem"},{"issue":"4","key":"1094_CR155","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.humimm.2020.12.005","volume":"82","author":"A Churov","year":"2021","unstructured":"Churov A, Zhulai G. Targeting adenosine and regulatory T cells in cancer immunotherapy. Hum Immunol. 2021;82(4):270\u20138. https:\/\/doi.org\/10.1016\/j.humimm.2020.12.005.","journal-title":"Hum Immunol"},{"issue":"22","key":"1094_CR156","doi-asserted-by":"publisher","first-page":"16573","DOI":"10.1021\/acs.jmedchem.1c01155","volume":"64","author":"W Yan","year":"2021","unstructured":"Yan W, et al. Structure-Based design of Dual-Acting compounds targeting adenosine A(2A) receptor and histone deacetylase as novel tumor immunotherapeutic agents. J Med Chem. 2021;64(22):16573\u201397. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01155.","journal-title":"J Med Chem"},{"issue":"12","key":"1094_CR157","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.2217\/epi-2016-0110","volume":"8","author":"DL Marks","year":"2016","unstructured":"Marks DL, Olson RL, Fernandez-Zapico ME. Epigenetic control of the tumor microenvironment. Epigenomics. 2016;8(12):1671\u201387. https:\/\/doi.org\/10.2217\/epi-2016-0110.","journal-title":"Epigenomics"},{"issue":"9","key":"1094_CR158","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41423-020-0505-9","volume":"17","author":"X Pan","year":"2020","unstructured":"Pan X, Zheng L. Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment. Cell Mol Immunol. 2020;17(9):940\u201353. https:\/\/doi.org\/10.1038\/s41423-020-0505-9.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"1094_CR159","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168(4):724\u201340. https:\/\/doi.org\/10.1016\/j.cell.2017.01.016.","journal-title":"Cell"},{"issue":"6","key":"1094_CR160","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","volume":"30","author":"YR Murciano-Goroff","year":"2020","unstructured":"Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30(6):507\u201319. https:\/\/doi.org\/10.1038\/s41422-020-0337-2.","journal-title":"Cell Res"},{"issue":"3","key":"1094_CR161","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/immuno1030012","volume":"1","author":"TM Hulen","year":"2021","unstructured":"Hulen TM, Chamberlain CA, Svane IM, Met \u00d6. ACT up TIL now: the evolution of tumor-infiltrating lymphocytes in adoptive cell therapy for the treatment of solid tumors. Immuno. 2021;1(3):194\u2013211.","journal-title":"Immuno"},{"key":"1094_CR162","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2017","unstructured":"Newick K, O\u2019Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annu Rev Med. 2017;68:139\u201352. https:\/\/doi.org\/10.1146\/annurev-med-062315-120245.","journal-title":"Annu Rev Med"},{"issue":"3","key":"1094_CR163","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/s1470-2045(19)30823-x","volume":"21","author":"AK Singh","year":"2020","unstructured":"Singh AK, McGuirk JP. CAR T cells: continuation in a revolution of immunotherapy. Lancet Oncol. 2020;21(3):e168\u201378. https:\/\/doi.org\/10.1016\/s1470-2045(19)30823-x.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1094_CR164","doi-asserted-by":"publisher","first-page":"101285","DOI":"10.1016\/j.beha.2021.101285","volume":"34","author":"E Tan","year":"2021","unstructured":"Tan E, Gakhar N, Kirtane K. TCR gene-engineered cell therapy for solid tumors. Best Pract Res Clin Haematol. 2021;34(3):101285. https:\/\/doi.org\/10.1016\/j.beha.2021.101285.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"1094_CR165","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40264-018-0779-3","volume":"42","author":"B Wolf","year":"2019","unstructured":"Wolf B, et al. Safety and tolerability of adoptive cell therapy in cancer. Drug Saf. 2019;42(2):315\u201334. https:\/\/doi.org\/10.1007\/s40264-018-0779-3.","journal-title":"Drug Saf"},{"issue":"4","key":"1094_CR166","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41571-021-00490-4","volume":"18","author":"HL Kaufman","year":"2021","unstructured":"Kaufman HL, Maciorowski D. Advancing oncolytic virus therapy by Understanding the biology. Nat Rev Clin Oncol. 2021;18(4):197\u20138. https:\/\/doi.org\/10.1038\/s41571-021-00490-4.","journal-title":"Nat Rev Clin Oncol"},{"key":"1094_CR167","doi-asserted-by":"publisher","unstructured":"Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene Laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers (Basel). 2021;13(6). https:\/\/doi.org\/10.3390\/cancers13061383.","DOI":"10.3390\/cancers13061383"},{"issue":"4","key":"1094_CR168","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.Cd-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u0101o MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11(4):933\u201359. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1808.","journal-title":"Cancer Discov"},{"issue":"1","key":"1094_CR169","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41423-019-0341-y","volume":"17","author":"Z Liu","year":"2020","unstructured":"Liu Z, Han C, Fu YX. Targeting innate sensing in the tumor microenvironment to improve immunotherapy. Cell Mol Immunol. 2020;17(1):13\u201326. https:\/\/doi.org\/10.1038\/s41423-019-0341-y.","journal-title":"Cell Mol Immunol"},{"key":"1094_CR170","doi-asserted-by":"publisher","unstructured":"Pezzani R, et al. Synergistic effects of plant derivatives and conventional chemotherapeutic agents: an update on the cancer perspective. Med (Kaunas). 2019;55(4). https:\/\/doi.org\/10.3390\/medicina55040110.","DOI":"10.3390\/medicina55040110"},{"key":"1094_CR171","doi-asserted-by":"publisher","first-page":"158DOI","DOI":"10.3389\/fphar.2017.00158","volume":"8","author":"KR Roell","year":"2017","unstructured":"Roell KR, Reif DM, Motsinger-Reif AA. An introduction to terminology and methodology of chemical Synergy-Perspectives from across disciplines. Front Pharmacol. 2017;8:158DOI. https:\/\/doi.org\/10.3389\/fphar.2017.00158.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1094_CR172","doi-asserted-by":"publisher","first-page":"e00149","DOI":"10.1002\/prp2.149","volume":"3","author":"J Foucquier","year":"2015","unstructured":"Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3(3):e00149. https:\/\/doi.org\/10.1002\/prp2.149.","journal-title":"Pharmacol Res Perspect"},{"issue":"23","key":"1094_CR173","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022\u201343. https:\/\/doi.org\/10.18632\/oncotarget.16723.","journal-title":"Oncotarget"},{"key":"1094_CR174","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1476-4598-12-86","volume":"12","author":"B Hoesel","year":"2013","unstructured":"Hoesel B, Schmid JA. The complexity of NF-\u03baB signaling in inflammation and cancer. Mol Cancer. 2013;12:86. https:\/\/doi.org\/10.1186\/1476-4598-12-86.","journal-title":"Mol Cancer"},{"issue":"1","key":"1094_CR175","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ymthe.2020.09.004","volume":"29","author":"ZJ Lyu","year":"2021","unstructured":"Lyu ZJ, et al. Recurrent ZNF83-E293V mutation promotes bladder cancer progression through the NF-\u03baB pathway via transcriptional dysregulation of S100A8. Mol Ther. 2021;29(1):275\u201390. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.004.","journal-title":"Mol Ther"},{"key":"1094_CR176","doi-asserted-by":"publisher","first-page":"107538DOI","DOI":"10.1016\/j.pharmthera.2020.107538","volume":"211","author":"SE Thomas-Jardin","year":"2020","unstructured":"Thomas-Jardin SE, Dahl H, Nawas AF, Bautista M, Delk NA. NF-\u03baB signaling promotes castration-resistant prostate cancer initiation and progression. Pharmacol Ther. 2020;211:107538DOI. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107538.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"1094_CR177","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.it.2022.07.004","volume":"43","author":"D Capece","year":"2022","unstructured":"Capece D, et al. NF-\u03baB: blending metabolism, immunity, and inflammation. Trends Immunol. 2022;43(9):757\u201375. https:\/\/doi.org\/10.1016\/j.it.2022.07.004.","journal-title":"Trends Immunol"},{"key":"1094_CR178","doi-asserted-by":"publisher","unstructured":"Giordano A, Tommonaro G. Curcumin and cancer. Nutrients. 2019;11(10). https:\/\/doi.org\/10.3390\/nu11102376.","DOI":"10.3390\/nu11102376"},{"issue":"9","key":"1094_CR179","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1016\/j.xphs.2021.06.004","volume":"110","author":"MA Abdel-Hakeem","year":"2021","unstructured":"Abdel-Hakeem MA, Mongy S, Hassan B, Tantawi OI, Badawy I. Curcumin loaded Chitosan-Protamine nanoparticles revealed antitumor activity via suppression of NF-\u03baB, Proinflammatory cytokines and Bcl-2 gene expression in the breast cancer cells. J Pharm Sci. 2021;110(9):3298\u2013305. https:\/\/doi.org\/10.1016\/j.xphs.2021.06.004.","journal-title":"J Pharm Sci"},{"issue":"1","key":"1094_CR180","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3892\/or.2020.7600","volume":"44","author":"W Li","year":"2020","unstructured":"Li W, et al. Curcumin inhibits pancreatic cancer cell invasion and EMT by interfering with tumor\u2013stromal crosstalk under hypoxic conditions via the IL\u20136\/ERK\/NF\u2013\u03baB axis. Oncol Rep. 2020;44(1):382\u201392. https:\/\/doi.org\/10.3892\/or.2020.7600.","journal-title":"Oncol Rep"},{"issue":"3","key":"1094_CR181","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jhep.2015.04.018","volume":"63","author":"JU Marquardt","year":"2015","unstructured":"Marquardt JU, et al. Curcumin effectively inhibits oncogenic NF-\u03baB signaling and restrains stemness features in liver cancer. J Hepatol. 2015;63(3):661\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2015.04.018.","journal-title":"J Hepatol"},{"key":"1094_CR182","doi-asserted-by":"publisher","first-page":"1014933DOI","DOI":"10.3389\/fphar.2022.1014933","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, Shen Z, Zhu T, Lu W, Fu Y. Curcumin enhances the anti-cancer efficacy of Paclitaxel in ovarian cancer by regulating the miR-9-5p\/BRCA1 axis. Front Pharmacol. 2022;13:1014933DOI. https:\/\/doi.org\/10.3389\/fphar.2022.1014933.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1094_CR183","doi-asserted-by":"publisher","first-page":"375","DOI":"10.22088\/cjim.13.2.9","volume":"13","author":"D Santosa","year":"2022","unstructured":"Santosa D, et al. Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial. Casp J Intern Med. 2022;13(2):375\u201384. https:\/\/doi.org\/10.22088\/cjim.13.2.9.","journal-title":"Casp J Intern Med"},{"issue":"2","key":"1094_CR184","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.canlet.2010.12.015","volume":"301","author":"H Huang","year":"2011","unstructured":"Huang H, et al. Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Lett. 2011;301(2):221\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2010.12.015.","journal-title":"Cancer Lett"},{"issue":"2","key":"1094_CR185","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/bjc.2013.752","volume":"110","author":"LH Wang","year":"2014","unstructured":"Wang LH, et al. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-\u03baB and MAPK\/HO-1 signalling. Br J Cancer. 2014;110(2):341\u201352. https:\/\/doi.org\/10.1038\/bjc.2013.752.","journal-title":"Br J Cancer"},{"key":"1094_CR186","doi-asserted-by":"publisher","unstructured":"Suchors C, Kim J. Canonical Hedgehog pathway and noncanonical GLI transcription factor activation in cancer. Cells. 2022;11(16). https:\/\/doi.org\/10.3390\/cells11162523.","DOI":"10.3390\/cells11162523"},{"issue":"2","key":"1094_CR187","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2012.09.021","volume":"151","author":"R Teperino","year":"2012","unstructured":"Teperino R, et al. Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat. Cell. 2012;151(2):414\u201326. https:\/\/doi.org\/10.1016\/j.cell.2012.09.021.","journal-title":"Cell"},{"issue":"7211","key":"1094_CR188","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nature07275","volume":"455","author":"RL Yauch","year":"2008","unstructured":"Yauch RL, et al. A paracrine requirement for Hedgehog signalling in cancer. Nature. 2008;455(7211):406\u201310. https:\/\/doi.org\/10.1038\/nature07275.","journal-title":"Nature"},{"issue":"6","key":"1094_CR189","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ptr.5809","volume":"31","author":"F Kalalinia","year":"2017","unstructured":"Kalalinia F, Karimi-Sani I. Anticancer properties of solamargine: A systematic review. Phytother Res. 2017;31(6):858\u201370. https:\/\/doi.org\/10.1002\/ptr.5809.","journal-title":"Phytother Res"},{"key":"1094_CR190","doi-asserted-by":"publisher","first-page":"802168","DOI":"10.3389\/fphar.2022.802168","volume":"13","author":"Y Han","year":"2022","unstructured":"Han Y, et al. Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids. Front Pharmacol. 2022;13:802168. https:\/\/doi.org\/10.3389\/fphar.2022.802168.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1094_CR191","first-page":"1426","volume":"60","author":"L Gamet-Payrastre","year":"2000","unstructured":"Gamet-Payrastre L, et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 2000;60(5):1426\u201333.","journal-title":"Cancer Res"},{"issue":"1","key":"1094_CR192","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3892\/ol.2017.7293","volume":"15","author":"F Wang","year":"2018","unstructured":"Wang F, et al. Sulforaphane reverses gefitinib tolerance in human lung cancer cells via modulation of Sonic Hedgehog signaling. Oncol Lett. 2018;15(1):109\u201314. https:\/\/doi.org\/10.3892\/ol.2017.7293.","journal-title":"Oncol Lett"},{"key":"1094_CR193","doi-asserted-by":"publisher","unstructured":"Vera-Ramirez L, Vodnala SK, Nini R, Hunter KW, Green JE. Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. Nat Commun. 2018;9(1):1944.https:\/\/doi.org\/10.1038\/s41467-018-04070-6","DOI":"10.1038\/s41467-018-04070-6"},{"issue":"2","key":"1094_CR194","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41419-017-0170-9","volume":"9","author":"AT Ouchida","year":"2018","unstructured":"Ouchida AT, et al. Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death. Cell Death Dis. 2018;9(2):138. https:\/\/doi.org\/10.1038\/s41419-017-0170-9.","journal-title":"Cell Death Dis"},{"issue":"43","key":"1094_CR195","doi-asserted-by":"publisher","first-page":"24188","DOI":"10.1039\/c8ra03666g","volume":"8","author":"J Zeng","year":"2018","unstructured":"Zeng J, et al. Current knowledge and development of Hederagenin as a promising medicinal agent: a comprehensive review. RSC Adv. 2018;8(43):24188\u2013202. https:\/\/doi.org\/10.1039\/c8ra03666g.","journal-title":"RSC Adv"},{"issue":"8","key":"1094_CR196","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41419-020-02880-5","volume":"11","author":"K Wang","year":"2020","unstructured":"Wang K, et al. Hederagenin potentiated cisplatin- and paclitaxel-mediated cytotoxicity by impairing autophagy in lung cancer cells. Cell Death Dis. 2020;11(8):611. https:\/\/doi.org\/10.1038\/s41419-020-02880-5.","journal-title":"Cell Death Dis"},{"issue":"6","key":"1094_CR197","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1021\/jf105003n","volume":"59","author":"MY Lee","year":"2011","unstructured":"Lee MY, Liao MH, Tsai YN, Chiu KH, Wen HC. Identification and anti-human glioblastoma activity of Tagitinin C from tithonia diversifolia methanolic extract. J Agric Food Chem. 2011;59(6):2347\u201355. https:\/\/doi.org\/10.1021\/jf105003n.","journal-title":"J Agric Food Chem"},{"issue":"3","key":"1094_CR198","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.fitote.2010.11.002","volume":"82","author":"MH Liao","year":"2011","unstructured":"Liao MH, Lin WC, Wen HC, Pu HF. Tithonia diversifolia and its main active component Tagitinin C induce survivin Inhibition and G2\/M arrest in human malignant glioblastoma cells. Fitoterapia. 2011;82(3):331\u201341. https:\/\/doi.org\/10.1016\/j.fitote.2010.11.002.","journal-title":"Fitoterapia"},{"key":"1094_CR199","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.redox.2016.12.010","volume":"11","author":"JL Roh","year":"2017","unstructured":"Roh JL, Kim EH, Jang H, Shin D. Nrf2 Inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 2017;11:254\u201362. https:\/\/doi.org\/10.1016\/j.redox.2016.12.010.","journal-title":"Redox Biol"},{"issue":"11","key":"1094_CR200","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s41419-021-04367-3","volume":"12","author":"J Yang","year":"2021","unstructured":"Yang J, et al. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2\/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell Death Dis. 2021;12(11):1079. https:\/\/doi.org\/10.1038\/s41419-021-04367-3.","journal-title":"Cell Death Dis"},{"key":"1094_CR201","doi-asserted-by":"publisher","first-page":"153370DOI","DOI":"10.1016\/j.phymed.2020.153370","volume":"80","author":"JS Lou","year":"2021","unstructured":"Lou JS, et al. Ginkgetin derived from Ginkgo Biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2\/HO-1 axis in EGFR wild-type non-small-cell lung cancer. Phytomedicine. 2021;80:153370DOI. https:\/\/doi.org\/10.1016\/j.phymed.2020.153370.","journal-title":"Phytomedicine"},{"key":"1094_CR202","doi-asserted-by":"publisher","first-page":"102050DOI","DOI":"10.1016\/j.ceca.2019.06.004","volume":"82","author":"D Crott\u00e8s","year":"2019","unstructured":"Crott\u00e8s D, Jan LY. The multifaceted role of TMEM16A in cancer. Cell Calcium. 2019;82:102050DOI. https:\/\/doi.org\/10.1016\/j.ceca.2019.06.004.","journal-title":"Cell Calcium"},{"issue":"Pt A","key":"1094_CR203","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.ijbiomac.2022.11.123","volume":"223","author":"S Shi","year":"2022","unstructured":"Shi S, et al. Molecular mechanism of ion channel protein TMEM16A regulated by natural product of Narirutin for lung cancer adjuvant treatment. Int J Biol Macromol. 2022;223(Pt A):1145\u201357. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.11.123.","journal-title":"Int J Biol Macromol"},{"issue":"7","key":"1094_CR204","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11274-016-2073-9","volume":"32","author":"X Hu","year":"2016","unstructured":"Hu X, et al. Homoharringtonine production by endophytic fungus isolated from cephalotaxus hainanensis Li. World J Microbiol Biotechnol. 2016;32(7):110. https:\/\/doi.org\/10.1007\/s11274-016-2073-9.","journal-title":"World J Microbiol Biotechnol"},{"key":"1094_CR205","doi-asserted-by":"publisher","unstructured":"Guo S, et al. TMEM16A, a Homoharringtonine Receptor, as a potential endogenic target for lung cancer treatment. Int J Mol Sci. 2021;22(20). https:\/\/doi.org\/10.3390\/ijms222010930.","DOI":"10.3390\/ijms222010930"},{"issue":"6","key":"1094_CR206","doi-asserted-by":"publisher","first-page":"8698","DOI":"10.1002\/jcp.27529","volume":"234","author":"S Guo","year":"2019","unstructured":"Guo S, et al. Matrine is a novel inhibitor of the TMEM16A chloride channel with Antilung adenocarcinoma effects. J Cell Physiol. 2019;234(6):8698\u2013708. https:\/\/doi.org\/10.1002\/jcp.27529.","journal-title":"J Cell Physiol"},{"issue":"3","key":"1094_CR207","doi-asserted-by":"publisher","first-page":"101016","DOI":"10.1016\/j.jbc.2021.101016","volume":"297","author":"S Shi","year":"2021","unstructured":"Shi S, Ma B, Sun F, Qu C, An H. Theaflavin binds to a druggable pocket of TMEM16A channel and inhibits lung adenocarcinoma cell viability. J Biol Chem. 2021;297(3):101016. https:\/\/doi.org\/10.1016\/j.jbc.2021.101016.","journal-title":"J Biol Chem"},{"key":"1094_CR208","doi-asserted-by":"publisher","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9). https:\/\/doi.org\/10.3390\/ijms21093233.","DOI":"10.3390\/ijms21093233"},{"key":"1094_CR209","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ejmech.2019.05.053","volume":"180","author":"H Yin","year":"2019","unstructured":"Yin H, et al. Design, synthesis and biological evaluation of Chalcones as reversers of P-glycoprotein-mediated multidrug resistance. Eur J Med Chem. 2019;180:350\u201366. https:\/\/doi.org\/10.1016\/j.ejmech.2019.05.053.","journal-title":"Eur J Med Chem"},{"key":"1094_CR210","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/1476-4598-9-259","volume":"9","author":"MA Sabatino","year":"2010","unstructured":"Sabatino MA, et al. Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells. Mol Cancer. 2010;9:259. https:\/\/doi.org\/10.1186\/1476-4598-9-259.","journal-title":"Mol Cancer"},{"issue":"14","key":"1094_CR211","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.1158\/0008-5472.Can-05-0715","volume":"65","author":"RN Trivedi","year":"2005","unstructured":"Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res. 2005;65(14):6394\u2013400. https:\/\/doi.org\/10.1158\/0008-5472.Can-05-0715.","journal-title":"Cancer Res"},{"issue":"8","key":"1094_CR212","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786\u201392. https:\/\/doi.org\/10.1056\/NEJMoa044238.","journal-title":"N Engl J Med"},{"issue":"8","key":"1094_CR213","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1038\/s41375-019-0402-3","volume":"33","author":"NA McNeer","year":"2019","unstructured":"McNeer NA, et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. 2019;33(8):1934\u201343. https:\/\/doi.org\/10.1038\/s41375-019-0402-3.","journal-title":"Leukemia"},{"key":"1094_CR214","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.plipres.2016.03.004","volume":"63","author":"E Damiani","year":"2016","unstructured":"Damiani E, Ullrich SE. Understanding the connection between platelet-activating factor, a UV-induced lipid mediator of inflammation, immune suppression and skin cancer. Prog Lipid Res. 2016;63:14\u201327. https:\/\/doi.org\/10.1016\/j.plipres.2016.03.004.","journal-title":"Prog Lipid Res"},{"issue":"14","key":"1094_CR215","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1158\/0008-5472.Can-07-5771","volume":"68","author":"M Aponte","year":"2008","unstructured":"Aponte M, et al. Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR\/Src\/FAK\/paxillin in ovarian cancer. Cancer Res. 2008;68(14):5839\u201348. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-5771.","journal-title":"Cancer Res"},{"issue":"8","key":"1094_CR216","doi-asserted-by":"publisher","first-page":"13846","DOI":"10.18632\/oncotarget.14647","volume":"8","author":"B Yao","year":"2017","unstructured":"Yao B, et al. PAFR selectively mediates radioresistance and irradiation-induced autophagy suppression in prostate cancer cells. Oncotarget. 2017;8(8):13846\u201354. https:\/\/doi.org\/10.18632\/oncotarget.14647.","journal-title":"Oncotarget"},{"issue":"19","key":"1094_CR217","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1158\/0008-5472.Can-15-1062","volume":"75","author":"J Chen","year":"2015","unstructured":"Chen J, et al. Feed-Forward reciprocal activation of PAFR and STAT3 regulates Epithelial-Mesenchymal transition in Non-Small cell lung cancer. Cancer Res. 2015;75(19):4198\u2013210. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-1062.","journal-title":"Cancer Res"},{"issue":"40","key":"1094_CR218","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.1038\/onc.2014.434","volume":"34","author":"J Chen","year":"2015","unstructured":"Chen J, et al. Platelet-activating factor receptor-mediated PI3K\/AKT activation contributes to the malignant development of esophageal squamous cell carcinoma. Oncogene. 2015;34(40):5114\u201327. https:\/\/doi.org\/10.1038\/onc.2014.434.","journal-title":"Oncogene"},{"issue":"10","key":"1094_CR219","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/00029330-200705020-00013","volume":"120","author":"SH Xia","year":"2007","unstructured":"Xia SH, Fang DC. Pharmacological action and mechanisms of Ginkgolide B. Chin Med J (Engl). 2007;120(10):922\u20138.","journal-title":"Chin Med J (Engl)"},{"key":"1094_CR220","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.biopha.2018.10.084","volume":"109","author":"C Lou","year":"2019","unstructured":"Lou C, Lu H, Ma Z, Liu C, Zhang Y. Ginkgolide B enhances gemcitabine sensitivity in pancreatic cancer cell lines via inhibiting PAFR\/NF-\u043aB pathway. Biomed Pharmacother. 2019;109:563\u201372. https:\/\/doi.org\/10.1016\/j.biopha.2018.10.084.","journal-title":"Biomed Pharmacother"},{"key":"1094_CR221","doi-asserted-by":"publisher","unstructured":"Kawasaki K, et al. Ginkgolide B regulates CDDP chemoresistance in oral cancer via the Platelet-Activating factor receptor pathway. Cancers (Basel). 2021;13(24). https:\/\/doi.org\/10.3390\/cancers13246299.","DOI":"10.3390\/cancers13246299"},{"issue":"3","key":"1094_CR222","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/bjc.2014.323","volume":"111","author":"Y Yu","year":"2014","unstructured":"Yu Y, et al. The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy. Br J Cancer. 2014;111(3):515\u201324. https:\/\/doi.org\/10.1038\/bjc.2014.323.","journal-title":"Br J Cancer"},{"issue":"8","key":"1094_CR223","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nrc.2016.58","volume":"16","author":"G Ichim","year":"2016","unstructured":"Ichim G, Tait SW. A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer. 2016;16(8):539\u201348. https:\/\/doi.org\/10.1038\/nrc.2016.58.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1094_CR224","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc.2017.15","volume":"17","author":"R Chammas","year":"2017","unstructured":"Chammas R, de Sousa Andrade LN, Jancar S. Oncogenic effects of PAFR ligands produced in tumours upon chemotherapy and radiotherapy. Nat Rev Cancer. 2017;17(4):253. https:\/\/doi.org\/10.1038\/nrc.2017.15.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1094_CR225","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41419-018-0844-y","volume":"9","author":"Y Chen","year":"2018","unstructured":"Chen Y, et al. Prolyl isomerase Pin1: a promoter of cancer and a target for therapy. Cell Death Dis. 2018;9(9):883. https:\/\/doi.org\/10.1038\/s41419-018-0844-y.","journal-title":"Cell Death Dis"},{"issue":"31","key":"1094_CR226","doi-asserted-by":"publisher","first-page":"23829","DOI":"10.1074\/jbc.M109.092874","volume":"285","author":"GM Namgoong","year":"2010","unstructured":"Namgoong GM, et al. The Prolyl isomerase Pin1 induces LC-3 expression and mediates Tamoxifen resistance in breast cancer. J Biol Chem. 2010;285(31):23829\u201341. https:\/\/doi.org\/10.1074\/jbc.M109.092874.","journal-title":"J Biol Chem"},{"issue":"18","key":"1094_CR227","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1016\/j.cell.2021.07.020","volume":"184","author":"K Koikawa","year":"2021","unstructured":"Koikawa K, et al. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell. 2021;184(18):4753\u201371. https:\/\/doi.org\/10.1016\/j.cell.2021.07.020.","journal-title":"Cell"},{"key":"1094_CR228","doi-asserted-by":"publisher","first-page":"112785DOI","DOI":"10.1016\/j.biopha.2022.112785","volume":"148","author":"YT Tang","year":"2022","unstructured":"Tang YT, et al. Molecular biological mechanism of action in cancer therapies: juglone and its derivatives, the future of development. Biomed Pharmacother. 2022;148:112785DOI. https:\/\/doi.org\/10.1016\/j.biopha.2022.112785.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1094_CR229","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10495-016-1291-9","volume":"22","author":"S Sajadimajd","year":"2017","unstructured":"Sajadimajd S, Yazdanparast R. Sensitizing effect of juglone is mediated by down regulation of Notch1 signaling pathway in trastuzumab-resistant SKBR3 cells. Apoptosis. 2017;22(1):135\u201344. https:\/\/doi.org\/10.1007\/s10495-016-1291-9.","journal-title":"Apoptosis"},{"issue":"3","key":"1094_CR230","first-page":"1409","volume":"34","author":"HJ Yun","year":"2014","unstructured":"Yun HJ, Kim JY, Kim G, Choi HS. Prolyl-isomerase Pin1 impairs trastuzumab sensitivity by up-regulating fatty acid synthase expression. Anticancer Res. 2014;34(3):1409\u201316.","journal-title":"Anticancer Res"},{"issue":"20","key":"1094_CR231","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.2174\/0929867325666181105120911","volume":"27","author":"Y Nakatsu","year":"2020","unstructured":"Nakatsu Y, et al. Development of Pin1 inhibitors and their potential as therapeutic agents. Curr Med Chem. 2020;27(20):3314\u201329.","journal-title":"Curr Med Chem"},{"issue":"9","key":"1094_CR232","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.3390\/ijms21093233","volume":"21","author":"K Bukowski","year":"2020","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9):3233.","journal-title":"Int J Mol Sci"},{"key":"1094_CR233","doi-asserted-by":"publisher","first-page":"2172740","DOI":"10.1155\/2020\/2172740","volume":"2020","author":"MI Nasser","year":"2020","unstructured":"Nasser MI, et al. A comprehensive review on schisandrin B and its biological properties. Oxid Med Cell Longev. 2020;2020:2172740. https:\/\/doi.org\/10.1155\/2020\/2172740.","journal-title":"Oxid Med Cell Longev"},{"key":"1094_CR234","doi-asserted-by":"publisher","unstructured":"Yoganathan S, Alagaratnam A, Acharekar N, Kong J. Ellagic acid and schisandrins: natural biaryl polyphenols with therapeutic potential to overcome multidrug resistance in cancer. Cells. 2021;10(2). https:\/\/doi.org\/10.3390\/cells10020458.","DOI":"10.3390\/cells10020458"},{"issue":"1","key":"1094_CR235","doi-asserted-by":"publisher","first-page":"8419","DOI":"10.1038\/s41598-017-08817-x","volume":"7","author":"S Wang","year":"2017","unstructured":"Wang S, et al. Schisandrin B reverses doxorubicin resistance through inhibiting P-glycoprotein and promoting proteasome-mediated degradation of survivin. Sci Rep. 2017;7(1):8419. https:\/\/doi.org\/10.1038\/s41598-017-08817-x.","journal-title":"Sci Rep"},{"issue":"2","key":"1094_CR236","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.bbrc.2005.07.097","volume":"335","author":"P Qiangrong","year":"2005","unstructured":"Qiangrong P, Wang T, Lu Q, Hu X. Schisandrin B\u2013a novel inhibitor of P-glycoprotein. Biochem Biophys Res Commun. 2005;335(2):406\u201311. https:\/\/doi.org\/10.1016\/j.bbrc.2005.07.097.","journal-title":"Biochem Biophys Res Commun"},{"key":"1094_CR237","doi-asserted-by":"publisher","unstructured":"Teng YN, Wang CCN, Liao WC, Lan YH, Hung CC. Caffeic acid attenuates Multi-Drug resistance in cancer cells by inhibiting efflux function of human P-glycoprotein. Molecules. 2020;25(2). https:\/\/doi.org\/10.3390\/molecules25020247.","DOI":"10.3390\/molecules25020247"},{"key":"1094_CR238","doi-asserted-by":"publisher","first-page":"105975DOI","DOI":"10.1016\/j.phrs.2021.105975","volume":"175","author":"GEF Abd-Ellatef","year":"2022","unstructured":"Abd-Ellatef GEF, et al. Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein. Pharmacol Res. 2022;175:105975DOI. https:\/\/doi.org\/10.1016\/j.phrs.2021.105975.","journal-title":"Pharmacol Res"},{"issue":"4","key":"1094_CR239","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, et al. The PI3K pathway in human disease. Cell. 2017;170(4):605\u201335. https:\/\/doi.org\/10.1016\/j.cell.2017.07.029.","journal-title":"Cell"},{"issue":"8","key":"1094_CR240","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1158\/1078-0432.Ccr-04-2142","volume":"11","author":"DA Levine","year":"2005","unstructured":"Levine DA, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005;11(8):2875. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-2142.","journal-title":"Clin Cancer Res"},{"key":"1094_CR241","doi-asserted-by":"publisher","unstructured":"Xu D, Hu MJ, Wang YQ, Cui YL. Antioxidant activities of Quercetin and its complexes for medicinal application. Molecules. 2019;24(6). https:\/\/doi.org\/10.3390\/molecules24061123.","DOI":"10.3390\/molecules24061123"},{"issue":"7","key":"1094_CR242","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.7150\/ijbs.41686","volume":"16","author":"X Lu","year":"2020","unstructured":"Lu X, et al. Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K\/Akt signaling pathways. Int J Biol Sci. 2020;16(7):1121\u201334. https:\/\/doi.org\/10.7150\/ijbs.41686.","journal-title":"Int J Biol Sci"},{"key":"1094_CR243","doi-asserted-by":"publisher","unstructured":"Cai F, Zhang Y, Li J, Huang S, Gao R. Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K\/Akt\/mTOR pathway. Biosci Rep. 2020;40(3). https:\/\/doi.org\/10.1042\/bsr20192826.","DOI":"10.1042\/bsr20192826"},{"issue":"1","key":"1094_CR244","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2007.02.002","volume":"82","author":"YL Shi","year":"2007","unstructured":"Shi YL, Li MF. Biological effects of toosendanin, a triterpenoid extracted from Chinese traditional medicine. Prog Neurobiol. 2007;82(1):1\u201310. https:\/\/doi.org\/10.1016\/j.pneurobio.2007.02.002.","journal-title":"Prog Neurobiol"},{"key":"1094_CR245","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bcp.2018.03.022","volume":"152","author":"W Kai","year":"2018","unstructured":"Kai W, et al. Natural product Toosendanin reverses the resistance of human breast cancer cells to adriamycin as a novel PI3K inhibitor. Biochem Pharmacol. 2018;152:153\u201364. https:\/\/doi.org\/10.1016\/j.bcp.2018.03.022.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"1094_CR246","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1002\/jcb.26502","volume":"119","author":"BG Zhou","year":"2018","unstructured":"Zhou BG, Wei CS, Zhang S, Zhang Z, Gao HM. Matrine reversed multidrug resistance of breast cancer MCF-7\/ADR cells through PI3K\/AKT signaling pathway. J Cell Biochem. 2018;119(5):3885\u201391. https:\/\/doi.org\/10.1002\/jcb.26502.","journal-title":"J Cell Biochem"},{"issue":"2","key":"1094_CR247","doi-asserted-by":"publisher","first-page":"240","DOI":"10.38212\/2224-6614.3269","volume":"29","author":"MC Hsu","year":"2021","unstructured":"Hsu MC, Guo BC, Chen CH, Hu PA, Lee TS. Apigenin ameliorates hepatic lipid accumulation by activating the autophagy-mitochondria pathway. J Food Drug Anal. 2021;29(2):240\u201354. https:\/\/doi.org\/10.38212\/2224-6614.3269.","journal-title":"J Food Drug Anal"},{"issue":"4","key":"1094_CR248","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/MPA.0b013e318193a074","volume":"38","author":"MJ Strouch","year":"2009","unstructured":"Strouch MJ, et al. The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells. Pancreas. 2009;38(4):409\u201315. https:\/\/doi.org\/10.1097\/MPA.0b013e318193a074.","journal-title":"Pancreas"},{"key":"1094_CR249","doi-asserted-by":"publisher","unstructured":"Du B, Shim JS. Targeting Epithelial-Mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules. 2016;21(7). https:\/\/doi.org\/10.3390\/molecules21070965.","DOI":"10.3390\/molecules21070965"},{"key":"1094_CR250","doi-asserted-by":"publisher","unstructured":"BeLow M, Osipo C. Notch signaling in breast cancer: A role in drug resistance. Cells. 2020;9(10). https:\/\/doi.org\/10.3390\/cells9102204.","DOI":"10.3390\/cells9102204"},{"issue":"21","key":"1094_CR251","doi-asserted-by":"publisher","first-page":"8543","DOI":"10.1074\/jbc.RA118.006983","volume":"294","author":"E Farah","year":"2019","unstructured":"Farah E, et al. NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. J Biol Chem. 2019;294(21):8543\u201354. https:\/\/doi.org\/10.1074\/jbc.RA118.006983.","journal-title":"J Biol Chem"},{"issue":"1","key":"1094_CR252","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/0008-5472.Can-12-1733","volume":"73","author":"YP Liu","year":"2013","unstructured":"Liu YP, et al. Cisplatin selects for multidrug-resistant CD133\u2009+\u2009cells in lung adenocarcinoma by activating Notch signaling. Cancer Res. 2013;73(1):406\u201316. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-1733.","journal-title":"Cancer Res"},{"issue":"17","key":"1094_CR253","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.7150\/jca.30690","volume":"10","author":"G He","year":"2019","unstructured":"He G, et al. Effects of Notch signaling pathway in cervical cancer by Curcumin mediated photodynamic therapy and its possible mechanisms in vitro and in vivo. J Cancer. 2019;10(17):4114\u201322. https:\/\/doi.org\/10.7150\/jca.30690.","journal-title":"J Cancer"},{"issue":"4","key":"1094_CR254","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/jcb.23019","volume":"112","author":"S Liao","year":"2011","unstructured":"Liao S, et al. Inhibitory effect of Curcumin on oral carcinoma CAL-27 cells via suppression of Notch-1 and NF-\u03baB signaling pathways. J Cell Biochem. 2011;112(4):1055\u201365. https:\/\/doi.org\/10.1002\/jcb.23019.","journal-title":"J Cell Biochem"},{"issue":"5","key":"1094_CR255","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.cell.2015.01.043","volume":"160","author":"N Oshimori","year":"2015","unstructured":"Oshimori N, Oristian D, Fuchs E. TGF-\u03b2 promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell. 2015;160(5):963\u201376. https:\/\/doi.org\/10.1016\/j.cell.2015.01.043.","journal-title":"Cell"},{"issue":"1","key":"1094_CR256","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13045-022-01367-4","volume":"15","author":"JD Cropper","year":"2022","unstructured":"Cropper JD, et al. PARP1-MGMT complex underpins pathway crosstalk in O(6)-methylguanine repair. J Hematol Oncol. 2022;15(1):146. https:\/\/doi.org\/10.1186\/s13045-022-01367-4.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1094_CR257","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/carcin\/bgv070","volume":"36","author":"A G\u00f6der","year":"2015","unstructured":"G\u00f6der A, et al. Lipoic acid inhibits the DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT) and triggers its depletion in colorectal cancer cells with concomitant autophagy induction. Carcinogenesis. 2015;36(8):817\u201331. https:\/\/doi.org\/10.1093\/carcin\/bgv070.","journal-title":"Carcinogenesis"},{"issue":"11","key":"1094_CR258","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/nm.3388","volume":"19","author":"CR Chong","year":"2013","unstructured":"Chong CR, J\u00e4nne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19(11):1389\u2013400. https:\/\/doi.org\/10.1038\/nm.3388.","journal-title":"Nat Med"},{"issue":"4","key":"1094_CR259","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.3892\/ol.2015.3599","volume":"10","author":"C Wang","year":"2015","unstructured":"Wang C, Wang W, Wang C, Tang Y, Tian H. Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer. Oncol Lett. 2015;10(4):2063\u20136. https:\/\/doi.org\/10.3892\/ol.2015.3599.","journal-title":"Oncol Lett"},{"issue":"1","key":"1094_CR260","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13046-020-01566-2","volume":"39","author":"X Yu","year":"2020","unstructured":"Yu X, et al. Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer. J Exp Clin Cancer Res. 2020;39(1):62. https:\/\/doi.org\/10.1186\/s13046-020-01566-2.","journal-title":"J Exp Clin Cancer Res"},{"issue":"30","key":"1094_CR261","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1200\/jco.2014.58.8533","volume":"33","author":"DR Pachman","year":"2015","unstructured":"Pachman DR, et al. Clinical course of Oxaliplatin-Induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol. 2015;33(30):3416\u201322. https:\/\/doi.org\/10.1200\/jco.2014.58.8533.","journal-title":"J Clin Oncol"},{"issue":"28","key":"1094_CR262","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/jco.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, et al. Prevention and management of Chemotherapy-Induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38(28):3325\u201348. https:\/\/doi.org\/10.1200\/jco.20.01399.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1094_CR263","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.tins.2021.10.014","volume":"45","author":"E Merlini","year":"2022","unstructured":"Merlini E, Coleman MP, Loreto A. Mitochondrial dysfunction as a trigger of programmed axon death. Trends Neurosci. 2022;45(1):53\u201363. https:\/\/doi.org\/10.1016\/j.tins.2021.10.014.","journal-title":"Trends Neurosci"},{"issue":"5","key":"1094_CR264","first-page":"3140","volume":"11","author":"W Cheng","year":"2019","unstructured":"Cheng W, Xiang W, Wang S, Xu K. Tanshinone IIA ameliorates oxaliplatin-induced neurotoxicity via mitochondrial protection and autophagy promotion. Am J Transl Res. 2019;11(5):3140\u20139.","journal-title":"Am J Transl Res"},{"issue":"8","key":"1094_CR265","doi-asserted-by":"publisher","first-page":"e04708","DOI":"10.1016\/j.heliyon.2020.e04708","volume":"6","author":"MA Kandeil","year":"2020","unstructured":"Kandeil MA, Gomaa SB, Mahmoud MO. The effect of some natural antioxidants against cisplatin-induced neurotoxicity in rats: behavioral testing. Heliyon. 2020;6(8):e04708. https:\/\/doi.org\/10.1016\/j.heliyon.2020.e04708.","journal-title":"Heliyon"},{"issue":"12","key":"1094_CR266","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1007\/s11064-021-03428-5","volume":"46","author":"G Ibrahim Fouad","year":"2021","unstructured":"Ibrahim Fouad G, Ahmed KA. Neuroprotective potential of Berberine against Doxorubicin-Induced toxicity in rat\u2019s brain. Neurochem Res. 2021;46(12):3247\u201363. https:\/\/doi.org\/10.1007\/s11064-021-03428-5.","journal-title":"Neurochem Res"},{"issue":"3","key":"1094_CR267","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3892\/ijmm.2017.2857","volume":"39","author":"M Sun","year":"2017","unstructured":"Sun M, et al. Anticancer effects of ginsenoside Rg3 (Review). Int J Mol Med. 2017;39(3):507\u201318. https:\/\/doi.org\/10.3892\/ijmm.2017.2857.","journal-title":"Int J Mol Med"},{"issue":"1","key":"1094_CR268","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3816\/CCC.2009.n.002","volume":"8","author":"MG Fakih","year":"2009","unstructured":"Fakih MG, Rustum YM. Does celecoxib have a role in the treatment of patients with colorectal cancer? Clin Colorectal Cancer. 2009;8(1):11\u20134. https:\/\/doi.org\/10.3816\/CCC.2009.n.002.","journal-title":"Clin Colorectal Cancer"},{"issue":"7","key":"1094_CR269","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ctrv.2008.05.002","volume":"34","author":"D Kweekel","year":"2008","unstructured":"Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and Pharmacogenetic factors associated with Irinotecan toxicity. Cancer Treat Rev. 2008;34(7):656\u201369. https:\/\/doi.org\/10.1016\/j.ctrv.2008.05.002.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"1094_CR270","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/00365521.2019.1575466","volume":"54","author":"K Ota","year":"2019","unstructured":"Ota K, et al. Fluoropyrimidine-induced intestinal mucosal injury is associated with the severity of chemotherapy-related diarrhea. Scand J Gastroenterol. 2019;54(2):227\u201332. https:\/\/doi.org\/10.1080\/00365521.2019.1575466.","journal-title":"Scand J Gastroenterol"},{"key":"1094_CR271","doi-asserted-by":"publisher","first-page":"153985DOI","DOI":"10.1016\/j.phymed.2022.153985","volume":"100","author":"Y Hussain","year":"2022","unstructured":"Hussain Y, Khan H, Efferth T, Alam W. Regulation of Endoplasmic reticulum stress by hesperetin: focus on antitumor and cytoprotective effects. Phytomedicine. 2022;100:153985DOI. https:\/\/doi.org\/10.1016\/j.phymed.2022.153985.","journal-title":"Phytomedicine"},{"issue":"46","key":"1094_CR272","doi-asserted-by":"publisher","first-page":"27958","DOI":"10.18632\/oncotarget.24563","volume":"9","author":"Y Yu","year":"2018","unstructured":"Yu Y, et al. Two birds, one stone: Hesperetin alleviates chemotherapy-induced diarrhea and potentiates tumor Inhibition. Oncotarget. 2018;9(46):27958\u201373. https:\/\/doi.org\/10.18632\/oncotarget.24563.","journal-title":"Oncotarget"},{"issue":"2","key":"1094_CR273","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1161\/circresaha.117.312395","volume":"122","author":"D Bernstein","year":"2018","unstructured":"Bernstein D. Anthracycline cardiotoxicity: worrisome enough to have you quaking? Circ Res. 2018;122(2):188\u201390. https:\/\/doi.org\/10.1161\/circresaha.117.312395.","journal-title":"Circ Res"},{"issue":"7","key":"1094_CR274","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/14787210.2021.1863145","volume":"19","author":"M Deng","year":"2021","unstructured":"Deng M, et al. Calycosin: a review of its Pharmacological effects and application prospects. Expert Rev Anti Infect Ther. 2021;19(7):911\u201325. https:\/\/doi.org\/10.1080\/14787210.2021.1863145.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1094_CR275","doi-asserted-by":"publisher","first-page":"1733834","DOI":"10.1155\/2022\/1733834","volume":"2022","author":"L Zhang","year":"2022","unstructured":"Zhang L, et al. Calycosin alleviates Doxorubicin-Induced cardiotoxicity and pyroptosis by inhibiting NLRP3 inflammasome activation. Oxid Med Cell Longev. 2022;2022:1733834. https:\/\/doi.org\/10.1155\/2022\/1733834.","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"1094_CR276","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/ptr.6557","volume":"34","author":"J Zhai","year":"2020","unstructured":"Zhai J, et al. Calycosin ameliorates doxorubicin-induced cardiotoxicity by suppressing oxidative stress and inflammation via the Sirtuin 1-NOD-like receptor protein 3 pathway. Phytother Res. 2020;34(3):649\u201359. https:\/\/doi.org\/10.1002\/ptr.6557.","journal-title":"Phytother Res"},{"key":"1094_CR277","doi-asserted-by":"publisher","first-page":"111375DOI","DOI":"10.1016\/j.biopha.2021.111375","volume":"137","author":"X Lu","year":"2021","unstructured":"Lu X, Lu L, Gao L, Wang Y, Wang W. Calycosin attenuates doxorubicin-induced cardiotoxicity via autophagy regulation in zebrafish models. Biomed Pharmacother. 2021;137:111375DOI. https:\/\/doi.org\/10.1016\/j.biopha.2021.111375.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"1094_CR278","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2174\/1381612824666180115105850","volume":"24","author":"M Karamanou","year":"2018","unstructured":"Karamanou M, Tsoucalas G, Pantos K, Androutsos G. Isolating Colchicine in 19th century: an old drug revisited. Curr Pharm Des. 2018;24(6):654\u20138. https:\/\/doi.org\/10.2174\/1381612824666180115105850.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"1094_CR279","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11864-020-0719-1","volume":"21","author":"T Shiga","year":"2020","unstructured":"Shiga T, Hiraide M. Cardiotoxicities of 5-Fluorouracil and other fluoropyrimidines. Curr Treat Options Oncol. 2020;21(4):27. https:\/\/doi.org\/10.1007\/s11864-020-0719-1.","journal-title":"Curr Treat Options Oncol"},{"key":"1094_CR280","doi-asserted-by":"publisher","first-page":"6194532","DOI":"10.1155\/2022\/6194532","volume":"2022","author":"S Safarpour","year":"2022","unstructured":"Safarpour S, et al. Colchicine ameliorates 5-Fluorouracil-Induced cardiotoxicity in rats. Oxid Med Cell Longev. 2022;2022:6194532. https:\/\/doi.org\/10.1155\/2022\/6194532.","journal-title":"Oxid Med Cell Longev"},{"issue":"7","key":"1094_CR281","doi-asserted-by":"publisher","first-page":"e2200060","DOI":"10.1002\/ardp.202200060","volume":"355","author":"S Safarpour","year":"2022","unstructured":"Safarpour S, et al. Cardioprotective effect of Silymarin nanoemulsion on 5-fluorouracil-induced cardiotoxicity in rats. Arch Pharm (Weinheim). 2022;355(7):e2200060. https:\/\/doi.org\/10.1002\/ardp.202200060.","journal-title":"Arch Pharm (Weinheim)"},{"issue":"5","key":"1094_CR282","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1142\/s0192415x22500537","volume":"50","author":"SH Wang","year":"2022","unstructured":"Wang SH, et al. Quercetin mitigates Cisplatin-Induced oxidative damage and apoptosis in cardiomyocytes through Nrf2\/HO-1 signaling pathway. Am J Chin Med. 2022;50(5):1281\u201398. https:\/\/doi.org\/10.1142\/s0192415x22500537.","journal-title":"Am J Chin Med"},{"key":"1094_CR283","doi-asserted-by":"publisher","first-page":"154471DOI","DOI":"10.1016\/j.phymed.2022.154471","volume":"107","author":"L Xu","year":"2022","unstructured":"Xu L, et al. Tanshinone IIA inhibits cardiomyocyte apoptosis and rescues cardiac function during doxorubicin-induced cardiotoxicity by activating the DAXX\/MEK\/ERK1\/2 pathway. Phytomedicine. 2022;107:154471DOI. https:\/\/doi.org\/10.1016\/j.phymed.2022.154471.","journal-title":"Phytomedicine"},{"issue":"4","key":"1094_CR284","doi-asserted-by":"publisher","first-page":"752","DOI":"10.21037\/cdt-19-707","volume":"10","author":"W Yu","year":"2020","unstructured":"Yu W, et al. Curcumin suppresses doxorubicin-induced cardiomyocyte pyroptosis via a PI3K\/Akt\/mTOR-dependent manner. Cardiovasc Diagn Ther. 2020;10(4):752\u201369. https:\/\/doi.org\/10.21037\/cdt-19-707.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"9","key":"1094_CR285","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/1061186x.2020.1722136","volume":"28","author":"M Al Fayi","year":"2020","unstructured":"Al Fayi M, Otifi H, Alshyarba M, Dera AA, Rajagopalan P. Thymoquinone and Curcumin combination protects cisplatin-induced kidney injury, nephrotoxicity by attenuating NF\u03baB, KIM-1 and ameliorating Nrf2\/HO-1 signalling. J Drug Target. 2020;28(9):913\u201322. https:\/\/doi.org\/10.1080\/1061186x.2020.1722136.","journal-title":"J Drug Target"},{"issue":"3","key":"1094_CR286","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00210-019-01734-y","volume":"393","author":"AO Maghmomeh","year":"2020","unstructured":"Maghmomeh AO, El-Gayar AM, El-Karef A, Abdel-Rahman N. Arsenic trioxide and Curcumin attenuate cisplatin-induced renal fibrosis in rats through targeting Hedgehog signaling. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(3):303\u201313. https:\/\/doi.org\/10.1007\/s00210-019-01734-y.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"2","key":"1094_CR287","first-page":"67","volume":"21","author":"P Zhang","year":"2000","unstructured":"Zhang P, et al. [Seven years\u2019 summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide\u2013an analysis of 242 cases]. Zhonghua Xue Ye Xue Za Zhi. 2000;21(2):67\u201370.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"2","key":"1094_CR288","doi-asserted-by":"publisher","first-page":"F427","DOI":"10.1152\/ajprenal.00258.2010","volume":"301","author":"DH Kim","year":"2011","unstructured":"Kim DH, et al. SIRT1 activation by Resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am J Physiol Ren Physiol. 2011;301(2):F427\u201335. https:\/\/doi.org\/10.1152\/ajprenal.00258.2010.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"9","key":"1094_CR289","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/jcb.25906","volume":"118","author":"AM Fuzer","year":"2017","unstructured":"Fuzer AM, Lee SY, Mott JD, Cominetti MR. [10]-Gingerol reverts malignant phenotype of breast cancer cells in 3D culture. J Cell Biochem. 2017;118(9):2693\u20139. https:\/\/doi.org\/10.1002\/jcb.25906.","journal-title":"J Cell Biochem"},{"key":"1094_CR290","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s13402-020-00539-z","volume":"43","author":"AC Baptista Moreno Martin","year":"2020","unstructured":"Baptista Moreno Martin AC, et al. [10]-Gingerol improves doxorubicin anticancer activity and decreases its side effects in triple negative breast cancer models. Cell Oncol. 2020;43:915\u201329.","journal-title":"Cell Oncol"},{"issue":"5","key":"1094_CR291","first-page":"1050","volume":"21","author":"A Unlu","year":"2016","unstructured":"Unlu A, Nayir E, Dogukan Kalenderoglu M, Kirca O, Ozdogan M. Curcumin (Turmeric) and cancer. J Buon. 2016;21(5):1050\u201360.","journal-title":"J Buon"},{"issue":"3","key":"1094_CR292","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/carcin\/bgv006","volume":"36","author":"S Toden","year":"2015","unstructured":"Toden S, et al. Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis. 2015;36(3):355\u201367. https:\/\/doi.org\/10.1093\/carcin\/bgv006.","journal-title":"Carcinogenesis"},{"issue":"18","key":"1094_CR293","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.7150\/jca.20196","volume":"8","author":"H Yang","year":"2017","unstructured":"Yang H, et al. Curcumin enhances the anticancer effect of 5-fluorouracil against gastric cancer through Down-Regulation of COX-2 and NF- \u03baB signaling pathways. J Cancer. 2017;8(18):3697\u2013706. https:\/\/doi.org\/10.7150\/jca.20196.","journal-title":"J Cancer"},{"issue":"7","key":"1094_CR294","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/mnfr.201200766","volume":"57","author":"V Aires","year":"2013","unstructured":"Aires V, et al. Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death. Mol Nutr Food Res. 2013;57(7):1170\u201381. https:\/\/doi.org\/10.1002\/mnfr.201200766.","journal-title":"Mol Nutr Food Res"},{"key":"1094_CR295","doi-asserted-by":"publisher","unstructured":"Buhrmann C, Shayan P, Goel A, Shakibaei M. Resveratrol regulates colorectal cancer cell invasion by modulation of focal adhesion molecules. Nutrients. 2017;9(10). https:\/\/doi.org\/10.3390\/nu9101073.","DOI":"10.3390\/nu9101073"},{"issue":"8","key":"1094_CR296","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.4161\/cbt.7.8.6302","volume":"7","author":"JY Chan","year":"2008","unstructured":"Chan JY, Phoo MS, Clement MV, Pervaiz S, Lee SC. Resveratrol displays Converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: the roles of caspase-6 and p53. Cancer Biol Ther. 2008;7(8):1305\u201312. https:\/\/doi.org\/10.4161\/cbt.7.8.6302.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"1094_CR297","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.canlet.2005.01.031","volume":"231","author":"S Garvin","year":"2006","unstructured":"Garvin S, Ollinger K, Dabrosin C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 2006;231(1):113\u201322. https:\/\/doi.org\/10.1016\/j.canlet.2005.01.031.","journal-title":"Cancer Lett"},{"issue":"15","key":"1094_CR298","doi-asserted-by":"publisher","first-page":"5253","DOI":"10.1158\/1078-0432.Ccr-03-0588","volume":"10","author":"Z Cao","year":"2004","unstructured":"Cao Z, Fang J, Xia C, Shi X, Jiang BH. trans-3,4,5\u2019-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res. 2004;10(15):5253\u201363. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-03-0588.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1094_CR299","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.3892\/mmr.2015.3675","volume":"12","author":"SH Lee","year":"2015","unstructured":"Lee SH, Koo BS, Park SY, Kim YM. Anti-angiogenic effects of Resveratrol in combination with 5-fluorouracil on B16 murine melanoma cells. Mol Med Rep. 2015;12(2):2777\u201383. https:\/\/doi.org\/10.3892\/mmr.2015.3675.","journal-title":"Mol Med Rep"},{"key":"1094_CR300","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3389\/fonc.2019.00769","volume":"9","author":"H Yang","year":"2019","unstructured":"Yang H, et al. Oridonin sensitizes Cisplatin-Induced apoptosis via AMPK\/Akt\/mTOR-Dependent autophagosome accumulation in A549 cells. Front Oncol. 2019;9:769. https:\/\/doi.org\/10.3389\/fonc.2019.00769.","journal-title":"Front Oncol"},{"key":"1094_CR301","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.fct.2017.02.020","volume":"103","author":"S Kalai Selvi","year":"2017","unstructured":"Kalai Selvi S, Vinoth A, Varadharajan T, Weng CF, Vijaya Padma V. Neferine augments therapeutic efficacy of cisplatin through ROS- mediated non-canonical autophagy in human lung adenocarcinoma (A549 cells). Food Chem Toxicol. 2017;103:28\u201340. https:\/\/doi.org\/10.1016\/j.fct.2017.02.020.","journal-title":"Food Chem Toxicol"},{"key":"1094_CR302","doi-asserted-by":"publisher","first-page":"110652DOI","DOI":"10.1016\/j.fct.2019.110652","volume":"132","author":"P Manogaran","year":"2019","unstructured":"Manogaran P, Beeraka NM, Huang CY, Vijaya Padma V. Neferine and isoliensinine enhance \u2018intracellular uptake of cisplatin\u2019 and induce \u2018ROS-mediated apoptosis\u2019 in colorectal cancer cells - A comparative study. Food Chem Toxicol. 2019;132:110652DOI. https:\/\/doi.org\/10.1016\/j.fct.2019.110652.","journal-title":"Food Chem Toxicol"},{"issue":"6","key":"1094_CR303","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/abbs\/gmw026","volume":"48","author":"S Hu","year":"2016","unstructured":"Hu S, et al. The synergistic effect of Resveratrol in combination with cisplatin on apoptosis via modulating autophagy in A549 cells. Acta Biochim Biophys Sin (Shanghai). 2016;48(6):528\u201335. https:\/\/doi.org\/10.1093\/abbs\/gmw026.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"11","key":"1094_CR304","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1158\/1535-7163.Mct-16-0332","volume":"15","author":"EH Kim","year":"2016","unstructured":"Kim EH, Jang H, Roh JL. A novel polyphenol conjugate sensitizes cisplatin-Resistant head and neck cancer cells to cisplatin via Nrf2 Inhibition. Mol Cancer Ther. 2016;15(11):2620\u20139. https:\/\/doi.org\/10.1158\/1535-7163.Mct-16-0332.","journal-title":"Mol Cancer Ther"},{"key":"1094_CR305","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.redox.2016.12.006","volume":"11","author":"R Sirota","year":"2017","unstructured":"Sirota R, Gibson D, Kohen R. The timing of caffeic acid treatment with cisplatin determines sensitization or resistance of ovarian carcinoma cell lines. Redox Biol. 2017;11:170\u20135. https:\/\/doi.org\/10.1016\/j.redox.2016.12.006.","journal-title":"Redox Biol"},{"issue":"1","key":"1094_CR306","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s13277-015-3773-8","volume":"37","author":"FF El-Senduny","year":"2016","unstructured":"El-Senduny FF, Badria FA, El-Waseef AM, Chauhan SC, Halaweish F. Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B. Tumour Biol. 2016;37(1):685\u201398. https:\/\/doi.org\/10.1007\/s13277-015-3773-8.","journal-title":"Tumour Biol"},{"issue":"9","key":"1094_CR307","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/1535370220917367","volume":"245","author":"Y Kurman","year":"2020","unstructured":"Kurman Y, et al. Cucurbitacin B and cisplatin induce the cell death pathways in MB49 mouse bladder cancer model. Exp Biol Med (Maywood). 2020;245(9):805\u201314. https:\/\/doi.org\/10.1177\/1535370220917367.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"S2","key":"1094_CR308","first-page":"20","volume":"26","author":"Q Hou","year":"2020","unstructured":"Hou Q, et al. Berberine: A traditional natural product with novel biological activities. Altern Ther Health Med. 2020;26(S2):20\u20137.","journal-title":"Altern Ther Health Med"},{"issue":"3","key":"1094_CR309","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3892\/or.2018.6552","volume":"40","author":"Y Huang","year":"2018","unstructured":"Huang Y, et al. Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to Sorafenib. Oncol Rep. 2018;40(3):1525\u201332. https:\/\/doi.org\/10.3892\/or.2018.6552.","journal-title":"Oncol Rep"},{"issue":"1","key":"1094_CR310","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40659-019-0243-6","volume":"52","author":"L Liu","year":"2019","unstructured":"Liu L, et al. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells. Biol Res. 2019;52(1):37. https:\/\/doi.org\/10.1186\/s40659-019-0243-6.","journal-title":"Biol Res"},{"issue":"1","key":"1094_CR311","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3892\/or.2016.4785","volume":"36","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Jing Z, Li Y, Mao W. Berberine in combination with cisplatin suppresses breast cancer cell growth through induction of DNA breaks and caspase-3-dependent apoptosis. Oncol Rep. 2016;36(1):567\u201372. https:\/\/doi.org\/10.3892\/or.2016.4785.","journal-title":"Oncol Rep"},{"key":"1094_CR312","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.synres.2020.100063","volume":"10","author":"N Bhagya","year":"2020","unstructured":"Bhagya N, Prabhu A, Rekha P, Chandrashekar K. Combination of tetrandrine and cisplatin synergises cytotoxicity and apoptosis in triple negative breast cancer. Synergy. 2020;10:100063.","journal-title":"Synergy"},{"key":"1094_CR313","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.phymed.2018.06.018","volume":"53","author":"TH Song","year":"2019","unstructured":"Song TH, et al. Dendrobine targeting JNK stress signaling to sensitize chemotoxicity of cisplatin against non-small cell lung cancer cells in vitro and in vivo. Phytomedicine. 2019;53:18\u201327. https:\/\/doi.org\/10.1016\/j.phymed.2018.06.018.","journal-title":"Phytomedicine"},{"key":"1094_CR314","doi-asserted-by":"publisher","first-page":"144556DOI","DOI":"10.1016\/j.gene.2020.144556","volume":"742","author":"L Zhu","year":"2020","unstructured":"Zhu L, et al. Sophoridine inhibits lung cancer cell growth and enhances cisplatin sensitivity through activation of the p53 and Hippo signaling pathways. Gene. 2020;742:144556DOI. https:\/\/doi.org\/10.1016\/j.gene.2020.144556.","journal-title":"Gene"},{"issue":"39","key":"1094_CR315","doi-asserted-by":"publisher","first-page":"63870","DOI":"10.18632\/oncotarget.11563","volume":"7","author":"BH Park","year":"2016","unstructured":"Park BH, et al. Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1\/2. Oncotarget. 2016;7(39):63870\u201386. https:\/\/doi.org\/10.18632\/oncotarget.11563.","journal-title":"Oncotarget"},{"issue":"9","key":"1094_CR316","doi-asserted-by":"publisher","first-page":"474","DOI":"10.5483\/BMBRep.2018.51.9.114","volume":"51","author":"Z Liu","year":"2018","unstructured":"Liu Z, Peng Q, Li Y, Gao Y. Resveratrol enhances cisplatin-induced apoptosis in human hepatoma cells via glutamine metabolism Inhibition. BMB Rep. 2018;51(9):474\u20139. https:\/\/doi.org\/10.5483\/BMBRep.2018.51.9.114.","journal-title":"BMB Rep"},{"issue":"1","key":"1094_CR317","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13048-018-0468-y","volume":"11","author":"H Wang","year":"2018","unstructured":"Wang H, Luo Y, Qiao T, Wu Z, Huang Z. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and Inhibition of cell migration and invasion. J Ovarian Res. 2018;11(1):93. https:\/\/doi.org\/10.1186\/s13048-018-0468-y.","journal-title":"J Ovarian Res"},{"issue":"28","key":"1094_CR318","doi-asserted-by":"publisher","first-page":"43337","DOI":"10.18632\/oncotarget.9712","volume":"7","author":"P Jiang","year":"2016","unstructured":"Jiang P, Wu X, Wang X, Huang W, Feng Q. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells. Oncotarget. 2016;7(28):43337\u201351. https:\/\/doi.org\/10.18632\/oncotarget.9712.","journal-title":"Oncotarget"},{"issue":"46","key":"1094_CR319","doi-asserted-by":"publisher","first-page":"75104","DOI":"10.18632\/oncotarget.12072","volume":"7","author":"S Arora","year":"2016","unstructured":"Arora S, et al. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells. Oncotarget. 2016;7(46):75104\u201317. https:\/\/doi.org\/10.18632\/oncotarget.12072.","journal-title":"Oncotarget"},{"key":"1094_CR320","doi-asserted-by":"publisher","unstructured":"Heyza JR, et al. Targeting the DNA repair endonuclease ERCC1-XPF with green tea polyphenol Epigallocatechin-3-Gallate (EGCG) and its prodrug to enhance cisplatin efficacy in human cancer cells. Nutrients. 2018;10(11). https:\/\/doi.org\/10.3390\/nu10111644.","DOI":"10.3390\/nu10111644"},{"key":"1094_CR321","doi-asserted-by":"publisher","unstructured":"Lee J, Choi MK, Song IS. Recent advances in doxorubicin formulation to enhance pharmacokinetics and tumor targeting. Pharmaceuticals (Basel). 2023;16(6). https:\/\/doi.org\/10.3390\/ph16060802.","DOI":"10.3390\/ph16060802"},{"key":"1094_CR322","doi-asserted-by":"publisher","first-page":"102095DOI","DOI":"10.1016\/j.nano.2019.102095","volume":"23","author":"Y Li","year":"2020","unstructured":"Li Y, et al. Co-delivery of Poria cocos extract and doxorubicin as an \u2018all-in-one\u2019 nanocarrier to combat breast cancer multidrug resistance during chemotherapy. Nanomedicine. 2020;23:102095DOI. https:\/\/doi.org\/10.1016\/j.nano.2019.102095.","journal-title":"Nanomedicine"},{"key":"1094_CR323","doi-asserted-by":"publisher","first-page":"36855","DOI":"10.1038\/srep36855","volume":"6","author":"SA Khaleel","year":"2016","unstructured":"Khaleel SA, Al-Abd AM, Ali AA, Abdel-Naim AB. Didox and Resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity. Sci Rep. 2016;6:36855. https:\/\/doi.org\/10.1038\/srep36855.","journal-title":"Sci Rep"},{"key":"1094_CR324","doi-asserted-by":"publisher","first-page":"109261DOI","DOI":"10.1016\/j.biopha.2019.109261","volume":"118","author":"WQ Cao","year":"2019","unstructured":"Cao WQ, et al. Enhanced anticancer efficiency of doxorubicin against human glioma by natural Borneol through triggering ROS-mediated signal. Biomed Pharmacother. 2019;118:109261DOI. https:\/\/doi.org\/10.1016\/j.biopha.2019.109261.","journal-title":"Biomed Pharmacother"},{"key":"1094_CR325","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cbi.2019.01.003","volume":"300","author":"K Piska","year":"2019","unstructured":"Piska K, et al. Synergistic anticancer activity of doxorubicin and Piperlongumine on DU-145 prostate cancer cells - The involvement of carbonyl reductase 1 Inhibition. Chem Biol Interact. 2019;300:40\u20138. https:\/\/doi.org\/10.1016\/j.cbi.2019.01.003.","journal-title":"Chem Biol Interact"},{"issue":"6","key":"1094_CR326","doi-asserted-by":"publisher","first-page":"5162","DOI":"10.3892\/mmr.2019.10180","volume":"19","author":"C Wen","year":"2019","unstructured":"Wen C, et al. Curcumin reverses doxorubicin resistance via Inhibition the efflux function of ABCB4 in doxorubicin\u2013resistant breast cancer cells. Mol Med Rep. 2019;19(6):5162\u20138. https:\/\/doi.org\/10.3892\/mmr.2019.10180.","journal-title":"Mol Med Rep"},{"key":"1094_CR327","doi-asserted-by":"publisher","first-page":"153329DOI","DOI":"10.1016\/j.phymed.2020.153329","volume":"78","author":"LN Zhang","year":"2020","unstructured":"Zhang LN, et al. Vielanin K enhances doxorubicin-induced apoptosis via activation of IRE1\u03b1- TRAF2 - JNK pathway and increases mitochondrial Ca(2 +) influx in MCF-7 and MCF-7\/MDR cells. Phytomedicine. 2020;78:153329DOI. https:\/\/doi.org\/10.1016\/j.phymed.2020.153329.","journal-title":"Phytomedicine"},{"key":"1094_CR328","doi-asserted-by":"publisher","first-page":"152885DOI","DOI":"10.1016\/j.phymed.2019.152885","volume":"58","author":"HL Gao","year":"2019","unstructured":"Gao HL, Xia YZ, Zhang YL, Yang L, Kong LY. Vielanin P enhances the cytotoxicity of doxorubicin via the Inhibition of PI3K\/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines. Phytomedicine. 2019;58:152885DOI. https:\/\/doi.org\/10.1016\/j.phymed.2019.152885.","journal-title":"Phytomedicine"},{"issue":"2","key":"1094_CR329","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11033-015-3939-x","volume":"43","author":"M Saghaeian Jazi","year":"2016","unstructured":"Saghaeian Jazi M, Samaei NM, Ghanei M, Shadmehr MB, Mowla SJ. Identification of new SOX2OT transcript variants highly expressed in human cancer cell lines and down regulated in stem cell differentiation. Mol Biol Rep. 2016;43(2):65\u201372. https:\/\/doi.org\/10.1007\/s11033-015-3939-x.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"1094_CR330","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13046-018-0689-3","volume":"37","author":"W Wang","year":"2018","unstructured":"Wang W, Chen D, Zhu K. SOX2OT variant 7 contributes to the synergistic interaction between EGCG and doxorubicin to kill osteosarcoma via autophagy and stemness Inhibition. J Exp Clin Cancer Res. 2018;37(1):37. https:\/\/doi.org\/10.1186\/s13046-018-0689-3.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1094_CR331","doi-asserted-by":"publisher","first-page":"131","DOI":"10.22034\/apjcp.2018.19.1.131","volume":"19","author":"N Namazi Sarvestani","year":"2018","unstructured":"Namazi Sarvestani N, Sepehri H, Delphi L, Moridi Farimani M. Eupatorin and salvigenin potentiate Doxorubicin-Induced apoptosis and cell cycle arrest in HT-29 and SW948 human colon cancer cells. Asian Pac J Cancer Prev. 2018;19(1):131\u20139. https:\/\/doi.org\/10.22034\/apjcp.2018.19.1.131.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1094_CR332","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.biopha.2017.09.008","volume":"95","author":"V Hanu\u0161ov\u00e1","year":"2017","unstructured":"Hanu\u0161ov\u00e1 V, et al. The effects of \u03b2-caryophyllene oxide and trans-nerolidol on the efficacy of doxorubicin in breast cancer cells and breast tumor-bearing mice. Biomed Pharmacother. 2017;95:828\u201336. https:\/\/doi.org\/10.1016\/j.biopha.2017.09.008.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"1094_CR333","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s10495-022-01750-z","volume":"27","author":"S Zhao","year":"2022","unstructured":"Zhao S, Tang Y, Wang R, Najafi M. Mechanisms of cancer cell death induction by paclitaxel: an updated review. Apoptosis. 2022;27(9):647\u201367.","journal-title":"Apoptosis"},{"issue":"4","key":"1094_CR334","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.prnil.2017.11.001","volume":"6","author":"S Erdogan","year":"2018","unstructured":"Erdogan S, Doganlar O, Doganlar ZB, Turkekul K. Naringin sensitizes human prostate cancer cells to Paclitaxel therapy. Prostate Int. 2018;6(4):126\u201335. https:\/\/doi.org\/10.1016\/j.prnil.2017.11.001.","journal-title":"Prostate Int"},{"key":"1094_CR335","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.biopha.2017.04.027","volume":"91","author":"S Kumari","year":"2017","unstructured":"Kumari S, Badana AK, Mohan GM, Shailender Naik G, Malla R. Synergistic effects of Coralyne and Paclitaxel on cell migration and proliferation of breast cancer cells lines. Biomed Pharmacother. 2017;91:436\u201345. https:\/\/doi.org\/10.1016\/j.biopha.2017.04.027.","journal-title":"Biomed Pharmacother"},{"key":"1094_CR336","doi-asserted-by":"publisher","first-page":"153342DOI","DOI":"10.1016\/j.phymed.2020.153342","volume":"79","author":"RM Liu","year":"2020","unstructured":"Liu RM, Xu P, Chen Q, Feng SL, Xie Y. A multiple-targets alkaloid Nuciferine overcomes paclitaxel-induced drug resistance in vitro and in vivo. Phytomedicine. 2020;79:153342DOI. https:\/\/doi.org\/10.1016\/j.phymed.2020.153342.","journal-title":"Phytomedicine"},{"key":"1094_CR337","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ejphar.2016.10.019","volume":"791","author":"MK Pal","year":"2016","unstructured":"Pal MK, et al. Synergistic effect of Piperine and Paclitaxel on cell fate via cyt-c, Bax\/Bcl-2-caspase-3 pathway in ovarian adenocarcinomas SKOV-3 cells. Eur J Pharmacol. 2016;791:751\u201362. https:\/\/doi.org\/10.1016\/j.ejphar.2016.10.019.","journal-title":"Eur J Pharmacol"},{"key":"1094_CR338","doi-asserted-by":"publisher","first-page":"110243DOI","DOI":"10.1016\/j.biopha.2020.110243","volume":"128","author":"L Rawat","year":"2020","unstructured":"Rawat L, Hegde H, Hoti SL, Nayak V. Piperlongumine induces ROS mediated cell death and synergizes Paclitaxel in human intestinal cancer cells. Biomed Pharmacother. 2020;128:110243DOI. https:\/\/doi.org\/10.1016\/j.biopha.2020.110243.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"1094_CR339","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3109\/07853890109002093","volume":"33","author":"H Joensuu","year":"2001","unstructured":"Joensuu H, Dimitrijevic S. Tyrosine kinase inhibitor Imatinib (STI571) as an anticancer agent for solid tumours. Ann Med. 2001;33(7):451\u20135. https:\/\/doi.org\/10.3109\/07853890109002093.","journal-title":"Ann Med"},{"key":"1094_CR340","doi-asserted-by":"publisher","unstructured":"Bilajac E, et al. Curcumin decreases viability and inhibits proliferation of Imatinib-Sensitive and Imatinib-Resistant chronic myeloid leukemia cell lines. Metabolites. 2022;13(1). https:\/\/doi.org\/10.3390\/metabo13010058.","DOI":"10.3390\/metabo13010058"},{"key":"1094_CR341","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ctim.2016.06.009","volume":"27","author":"M Demiray","year":"2016","unstructured":"Demiray M, et al. Successful treatment of c-kit-positive metastatic adenoid cystic carcinoma (ACC) with a combination of Curcumin plus imatinib: A case report. Complement Ther Med. 2016;27:108\u201313. https:\/\/doi.org\/10.1016\/j.ctim.2016.06.009.","journal-title":"Complement Ther Med"},{"issue":"4","key":"1094_CR342","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1358\/dot.2006.42.4.968648","volume":"42","author":"B Ramaswamy","year":"2006","unstructured":"Ramaswamy B, Puhalla S. Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. Drugs Today (Barc). 2006;42(4):265\u201379. https:\/\/doi.org\/10.1358\/dot.2006.42.4.968648.","journal-title":"Drugs Today (Barc)"},{"issue":"12","key":"1094_CR343","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1002\/jps.24637","volume":"104","author":"K Patel","year":"2015","unstructured":"Patel K, et al. Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in Triple-Negative breast cancer. J Pharm Sci. 2015;104(12):4417\u201326. https:\/\/doi.org\/10.1002\/jps.24637.","journal-title":"J Pharm Sci"},{"key":"1094_CR344","doi-asserted-by":"publisher","first-page":"128381","DOI":"10.1016\/j.molstruc.2020.128381","volume":"1217","author":"A Imiela","year":"2020","unstructured":"Imiela A, Surmacki J, Abramczyk H. Novel strategies of Raman imaging for monitoring the therapeutic benefit of Temozolomide in glioblastoma. J Mol Struct. 2020;1217:128381.","journal-title":"J Mol Struct"},{"key":"1094_CR345","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.2147\/ott.S174498","volume":"11","author":"WJ Liu","year":"2018","unstructured":"Liu WJ, et al. Natural Borneol is a novel chemosensitizer that enhances temozolomide-induced anticancer efficiency against human glioma by triggering mitochondrial dysfunction and reactive oxide species-mediated oxidative damage. Onco Targets Ther. 2018;11:5429\u201339. https:\/\/doi.org\/10.2147\/ott.S174498.","journal-title":"Onco Targets Ther"},{"key":"1094_CR346","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bbrc.2021.02.076","volume":"549","author":"WJ Ryu","year":"2021","unstructured":"Ryu WJ, Han G, Lee SH, Choi KY. Suppression of Wnt\/\u03b2-catenin and RAS\/ERK pathways provides a therapeutic strategy for gemcitabine-resistant pancreatic cancer. Biochem Biophys Res Commun. 2021;549:40\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2021.02.076.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1094_CR347","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/carcin\/bgy158","volume":"40","author":"E Norden","year":"2019","unstructured":"Norden E, Heiss EH. Urolithin A gains in antiproliferative capacity by reducing the glycolytic potential via the p53\/TIGAR axis in colon cancer cells. Carcinogenesis. 2019;40(1):93\u2013101. https:\/\/doi.org\/10.1093\/carcin\/bgy158.","journal-title":"Carcinogenesis"},{"issue":"6","key":"1094_CR348","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1021\/mp700113r","volume":"4","author":"P Anand","year":"2007","unstructured":"Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807\u201318. https:\/\/doi.org\/10.1021\/mp700113r.","journal-title":"Mol Pharm"},{"key":"1094_CR349","doi-asserted-by":"publisher","unstructured":"Tabanelli R, Brogi S, Calderone V. Improving Curcumin bioavailability: current strategies and future perspectives. Pharmaceutics. 2021;13(10). https:\/\/doi.org\/10.3390\/pharmaceutics13101715.","DOI":"10.3390\/pharmaceutics13101715"},{"key":"1094_CR350","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.phrs.2018.03.013","volume":"132","author":"D Pastorelli","year":"2018","unstructured":"Pastorelli D, et al. Phytosome complex of Curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: results of a prospective phase II trial. Pharmacol Res. 2018;132:72\u20139. https:\/\/doi.org\/10.1016\/j.phrs.2018.03.013.","journal-title":"Pharmacol Res"},{"issue":"18","key":"1094_CR351","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"key":"1094_CR352","doi-asserted-by":"publisher","unstructured":"Goldstein D, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107(2). https:\/\/doi.org\/10.1093\/jnci\/dju413.","DOI":"10.1093\/jnci\/dju413"},{"issue":"7","key":"1094_CR353","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/jn\/nxz029","volume":"149","author":"LM Howells","year":"2019","unstructured":"Howells LM, et al. Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial. J Nutr. 2019;149(7):1133\u20139. https:\/\/doi.org\/10.1093\/jn\/nxz029.","journal-title":"J Nutr"},{"key":"1094_CR354","doi-asserted-by":"publisher","first-page":"153218DOI","DOI":"10.1016\/j.phymed.2020.153218","volume":"70","author":"T Saghatelyan","year":"2020","unstructured":"Saghatelyan T, et al. Efficacy and safety of Curcumin in combination with Paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial. Phytomedicine. 2020;70:153218DOI. https:\/\/doi.org\/10.1016\/j.phymed.2020.153218.","journal-title":"Phytomedicine"},{"issue":"2","key":"1094_CR355","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/s0254-6272(08)60035-7","volume":"28","author":"P Wei","year":"2008","unstructured":"Wei P, et al. Relations between phlegm and generation and development of gastric cancer. J Tradit Chin Med. 2008;28(2):152\u20135. https:\/\/doi.org\/10.1016\/s0254-6272(08)60035-7.","journal-title":"J Tradit Chin Med"},{"issue":"3","key":"1094_CR356","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1089\/acu.2017.1226","volume":"29","author":"MT Greenwood","year":"2017","unstructured":"Greenwood MT, Dysbiosis. Spleen Qi, Phlegm, and complex difficulties. Med Acupunct. 2017;29(3):128\u201337. https:\/\/doi.org\/10.1089\/acu.2017.1226.","journal-title":"Med Acupunct"},{"issue":"6","key":"1094_CR357","first-page":"4135","volume":"32","author":"Q-y Jiang","year":"2017","unstructured":"Jiang Q-y, Yang X-j. Sun X-s. An aided diagnosis model of sub-health based on rough set and fuzzy mathematics: A case of TCM. J Intell Fuzzy Syst. 2017;32(6):4135\u201343.","journal-title":"J Intell Fuzzy Syst"},{"issue":"3","key":"1094_CR358","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/2472630317698683","volume":"22","author":"A Zarrinpar","year":"2017","unstructured":"Zarrinpar A. Metabolic pathway Inhibition in liver cancer. SLAS Technol. 2017;22(3):237\u201344. https:\/\/doi.org\/10.1177\/2472630317698683.","journal-title":"SLAS Technol"},{"issue":"1","key":"1094_CR359","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/153473540200100118","volume":"1","author":"KI Block","year":"2002","unstructured":"Block KI, Gyllenhaal C. Clinical corner: herb-drug interactions in cancer chemotherapy: theoretical concerns regarding drug metabolizing enzymes. Integr Cancer Ther. 2002;1(1):83\u20139. https:\/\/doi.org\/10.1177\/153473540200100118.","journal-title":"Integr Cancer Ther"},{"issue":"13","key":"1094_CR360","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2165\/11317010-000000000-00000","volume":"69","author":"AA Izzo","year":"2009","unstructured":"Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69(13):1777\u201398. https:\/\/doi.org\/10.2165\/11317010-000000000-00000.","journal-title":"Drugs"},{"issue":"7","key":"1094_CR361","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/nrc1887","volume":"6","author":"CD Scripture","year":"2006","unstructured":"Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006;6(7):546\u201358. https:\/\/doi.org\/10.1038\/nrc1887.","journal-title":"Nat Rev Cancer"},{"issue":"6a","key":"1094_CR362","first-page":"2341","volume":"13","author":"Z Zhang","year":"1993","unstructured":"Zhang Z, Hamilton SM, Stewart C, Strother A, Teel RW. Inhibition of liver microsomal cytochrome P450 activity and metabolism of the tobacco-specific Nitrosamine NNK by capsaicin and ellagic acid. Anticancer Res. 1993;13(6a):2341\u20136.","journal-title":"Anticancer Res"},{"issue":"1\u20134","key":"1094_CR363","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1515\/dmdi.2000.17.1-4.3","volume":"17","author":"TW Kensler","year":"2000","unstructured":"Kensler TW, Curphey TJ, Maxiutenko Y, Roebuck BD. Chemoprotection by organosulfur inducers of phase 2 enzymes: dithiolethiones and dithiins. Drug Metabol Drug Interact. 2000;17(1\u20134):3\u201322. https:\/\/doi.org\/10.1515\/dmdi.2000.17.1-4.3.","journal-title":"Drug Metabol Drug Interact"},{"issue":"11","key":"1094_CR364","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1124\/dmd.105.005892","volume":"33","author":"J Weiss","year":"2005","unstructured":"Weiss J, Sauer A, Frank A, Unger M. Extracts and Kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro. Drug Metab Dispos. 2005;33(11):1580\u20133. https:\/\/doi.org\/10.1124\/dmd.105.005892.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"1094_CR365","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1002\/ptr.5213","volume":"28","author":"SM Alsanad","year":"2014","unstructured":"Alsanad SM, Williamson EM, Howard RL. Cancer patients at risk of herb\/food supplement-drug interactions: a systematic review. Phytother Res. 2014;28(12):1749\u201355. https:\/\/doi.org\/10.1002\/ptr.5213.","journal-title":"Phytother Res"},{"issue":"1","key":"1094_CR366","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/10408398.2013.865590","volume":"57","author":"W Marx","year":"2017","unstructured":"Marx W, et al. Ginger-Mechanism of action in chemotherapy-induced nausea and vomiting: A review. Crit Rev Food Sci Nutr. 2017;57(1):141\u20136. https:\/\/doi.org\/10.1080\/10408398.2013.865590.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"8","key":"1094_CR367","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10552-017-0909-8","volume":"28","author":"S Parodi","year":"2017","unstructured":"Parodi S, Merlo FD, Stagnaro E. Coffee consumption and risk of non-Hodgkin\u2019s lymphoma: evidence from the Italian multicentre case-control study. Cancer Causes Control. 2017;28(8):867\u201376. https:\/\/doi.org\/10.1007\/s10552-017-0909-8.","journal-title":"Cancer Causes Control"},{"key":"1094_CR368","doi-asserted-by":"publisher","first-page":"1356DOI","DOI":"10.3389\/fonc.2019.01356","volume":"9","author":"PS Fasinu","year":"2019","unstructured":"Fasinu PS, Rapp GK. Herbal interaction with chemotherapeutic Drugs-A focus on clinically significant findings. Front Oncol. 2019;9:1356DOI. https:\/\/doi.org\/10.3389\/fonc.2019.01356.","journal-title":"Front Oncol"},{"key":"1094_CR369","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/ijn.S443692","volume":"19","author":"Y Lv","year":"2024","unstructured":"Lv Y, et al. Nano-Drug delivery systems based on natural products. Int J Nanomed. 2024;19:541\u201369. https:\/\/doi.org\/10.2147\/ijn.S443692.","journal-title":"Int J Nanomed"}],"container-title":["Nutrition &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12986-026-01094-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-026-01094-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12986-026-01094-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:47:32Z","timestamp":1774532852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12986-026-01094-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":369,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1094"],"URL":"https:\/\/doi.org\/10.1186\/s12986-026-01094-4","relation":{},"ISSN":["1743-7075"],"issn-type":[{"value":"1743-7075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not involve any animal or human experimental models. Hence, ethical approval is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"AI tools were employed solely for grammatical editing and language polishing.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}}],"article-number":"38"}}